(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/059408 A3

(51) International Patent Classification[7]: A61L 27/54, 31/16, 33/00, 33/04

(21) International Application Number: PCT/CA02/02017

(22) International Filing Date:
30 December 2002 (30.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/344,011 28 December 2001 (28.12.2001) US

(71) Applicant *(for all designated States except US)*: **ANGIOTECH PHARMACEUTICALS, INC.** [CA/CA]; 1618 Station Street, Vancouver, British Columbia V6A 1B6 (CA).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **SIGNORE, Pierre, E.** [CA/CA]; #207-2155 West 7th Avenue, Vancouver, British Columbia V6K 1X9 (CA).

(74) Agent: **BARRIGAR, Robert, H.**; Barrigar Intellectual Property Group, 830 - 1066 West Hastings Street, Vancouver, British Columbia V6E 3X1 (CA).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SURGICAL PATCHES WITH A BIOLOGICAL ACTIVE AGENT

(57) Abstract: Surgical patches are described which release an anti-inflammatory agent, an anti-platelet agent, an anticoagulant, a fibrinolytic agent, a cell-cycle inhibitor, and/or an anti-proliferative agent.

WO 03/059408 A3

COATED SURGICAL PATCHES

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to surgical patches coated with biologically active agents to prevent adverse tissue reaction to the patch.

Description of the Related Art

Primary closure and patch angioplasty are two techniques of arteriotomy closure used by surgeons after vascular procedures. In primary closure, the lips of the arterial wound are directly sutured to each other whereas an extra piece of material is sutured between the two lips during patch angioplasty. Patch angioplasty is preferred after procedures with a high rate of postoperative narrowing of the repaired vessel (endarterectomy of small carotid arteries for example). The added piece of material maintains the original diameter of the blood vessel and induces favorable local hemodynamics that otherwise may lead to recurrent stenosis.

Patch angioplasty can be performed with autologous tissue (typically the patient's saphenous vein) or synthetic material (expanded polytetrafluoroethylene or Dacron). Vein patches have drawbacks such as aneurismal degeneration and rupture. They require an additional incision to harvest the vein with associated morbidity. The patient veins may not be suitable for patching. Most importantly, the vein used for the patch will not be available for coronary artery bypass grafting should the patient require arterial reconstruction at a later time. For these reasons, the use of synthetic patches has become increasingly popular.

However, synthetic materials implanted in the vasculature induce thrombogenic, inflammatory and hyperproliferative responses. Immediately after implantation, platelets bind to the luminal surface of the prosthesis, triggering the coagulation cascade and inducing thrombus formation. Thrombus may grow large enough to cause distal ischemia (stroke in the case of carotid artery patches).

In the days following the procedure, inflammatory cells such as macrophages, lymphocytes and neutrophils adhere to the prosthetic lumen and also migrate into the peri-prosthetic space. These cells release cytokines that promote

smooth muscle cell migration from the adjacent vessel on the luminal surface of the patch. The cells further proliferate on the patch and secrete extracellular matrix. Depending on the porosity of the patch material, cells may also migrate through the pores of the patch from the surrounding tissue into the lumen. In both cases, hyperplasia causes plaque formation on the luminal surface of the patch and the adjacent vessels within a few weeks. This reduces luminal area in the treated blood vessel thus impeding blood flow to the distal tissues.

Therefore, there exists a need for a means and a method to prevent inflammatory reaction, thrombus formation and intimal hyperplasia on the luminal surface of synthetic patches. The present invention meets this need, and further, provides other, related advantages.

SUMMARY OF THE INVENTION

Briefly stated, the present invention involves methods of making and using surgical patches which release agents that prevent inflammatory reactions, thrombus formations and/or intimal hyperplasia. Representative examples of such agents include cell-cycle inhibitors such as taxanes, camptothecins, doxorubicin, immunosuppressive drugs (rapamycin, cyclosporines), bromocryptine, tubercidine, beta-lapachone, glucocorticoids, nonsteroidal anti-inflammatory drugs, cell cycle inhibitors, calcium channel blockers, calcium chelating agents, inhibitors of matrix metalloproteinases, methotrexate, thrombolytic agents, anti-platelet agents and anticoagulation agents. The presence of these agents, alone or in combination, on the patch will effectively prevent or inhibit local inflammatory reaction, prevent thrombus material from building up on the patch and stop cells from proliferating onto the patch.

Thus, within one aspect of the present invention surgical patches (*e.g.*, vascular patches) are provided which release an anti-inflammatory agent, an anti-platelet agent, an anticoagulant agent, fibrinolytic agents, a cell-cycle inhibitor agent, and/or an anti-proliferative agent. Within certain embodiments, the vascular patch is a synthetic patch (*e.g.*, made of Dacron). Within various embodiments, the anti-inflammatory agent is aspirin, ibuprofen, or a glucocorticoid drug, the anti-coagulant agent is heparin or hirudin, and the fibrinolytic agent is tissue plasminogen activator, streptokinase, or urokinase. Within other embodiments, the cell-cycle inhibitor agent is a taxane (e.g., paclitaxel or docetaxel), a vinca alkaloid (e.g., vinblastine or vincristine),

a podophyllotoxin (e.g., etoposide), an anthracycline (e.g., doxorubicin or mitoxantrone), or a platinum compound (e.g., cisplatin or carboplatin).

Also provided are methods for making surgical patches (*e.g.*, vascular patches) which release an anti-inflammatory agent, an anti-platelet agent, an anticoagulant, an anti-fibrinolytic agent, a cell-cycle inhibitor, and/or an anti-proliferative agent, comprising the step of coating at least a part (all or a portion such as the ends, or one side) of the patch (e.g., by spraying or dipping) with one of the factors or agents mentioned above. Alternative methods for generating patches (e.g., interweaving a patch with a coated thread, or absorbing a desired agent onto the patch) are described in more detail below. Within further embodiments, the factor or agent may be mixed or formulated with another compound or carrier (e.g., polymeric or non-polymeric). In one embodiment of the present invention, only one side of the patch is coated leaving the other side and most of the thickness of the patch untreated. In another embodiment, only parts (the edge for example) of the patch are coated.

Within other aspects of the invention, methods are provided for closing an opening in the biological tissue (e.g., the vasculature), comprising applying to the opening in a surgical patch as described herein. Within certain embodiments, the compound or composition may be applied by itself or in a carrier, which may be either polymeric, or non-polymeric. Within certain embodiments, the surgical patch is a vascular patch, which is sutured in place.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (*e.g.*, compounds, proteins, vectors, and their generation, etc.), and are therefore incorporated by reference in their entirety. When PCT applications are referred to it is also understood that the corresponding or cited U.S. applications or U.S. Patents are also incorporated by reference herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration showing sites of action within a biological pathway where Cell Cycle Inhibitors may act to inhibit the cell cycle.

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms that will be used hereinafter.

"Cell Cycle Inhibitor" as used herein refers to any protein, peptide, chemical or other molecule which delays or impairs a dividing cell's ability to progress through the cell cycle and replicate. Cell cycle inhibitors, which prolong or arrest mitosis (M-phase) or DNA synthesis (S-phase), are particularly effective for the purposes of this invention as they increase the dividing cell's sensitivity to the effects of radiation. A wide variety of methods may be utilized to determine the ability of a compound to inhibit the cell cycle including univariate analysis of cellular DNA content and multiparameter analysis (see the Examples).

I. PATCHES

Patches are small pieces of material used to mend a tear or a break to cover a hole or to strengthen a weak place. In medicine, surgical patches are pieces of synthetic material or biological tissue used to bridge together the defect between the edge of an incision or a gap in a biological structure (e.g., a vessel wall). Patches are also used after lung surgery to strengthen the repaired lung.

Synthetic vascular patches are available from medical device companies such as IMPRA, WL Gore, Sulzer Vascutek, Shelhigh, Bio Nova International, Intervascular and Aesculap for example. Tissue-based vascular patches are available from Biovascular and St Jude Medical. Representative examples of surgical patches are described in U.S. Patent Nos. 5,100,422; 5,104,400; 5,437,900; 5,456,711; 5,641,566; 5,645,915; 6,296,657; and 6,322,593.

Vascular patches as described herein can be, among other uses, during vascular surgery to repair blood vessels.

II. AGENTS

Anti-inflammatory agents

Inflammation occurs when cells of the immune system are activated in response to foreign agents or antigens. Leucocytes release lysosomal enzymes. Arachidonic acid is synthesized and eicosanoids, kinins, complement components and histamine are released. Cytokines have a powerful chemotactic effect on eosinophils,

neutrophils and macrophages. They also promote local hyperemia and vascular permeability. Superoxide anion is formed by the reduction of molecular oxygen, which stimulates the production of other reactive molecules such as hydrogen peroxide and hydroxyl radicals. The interaction of these substances with arachidonic acid results in the generation of more chemotatic substances, thus perpetuating the inflammatory process. Anti-inflammatory drugs inhibit one or several of the processes described above thus interfering with the inflammatory reaction.

Examples of anti-inflammatory drugs include but are not limited to nonsteroidal inflammatory drugs such as aspirin, ibuprofen, naproxen, fenoprofen, indomethacin, sulindac, meclofenamate, mefenamic acid, tolmetin, phenylbutazone, piroxicam, diflunisal apazone carprofen, flurbiprofen, diclofenac, ketoprofen; slow-acting anti-inflammatory drugs such as chloroquinine, hydroxychloroquinine, gold, penicillamine, levamisole; glucocorticoid drugs such as hydrocortisone, cortisone, dexamethasone, prednisone, fluocortolone, triamcinolone, fludrocortisone; statins such as pravastatin, fluvastatin, simvastatin, lovastatin; thromboxane inhibitors such as triazolopyrimidine; immunosuppressive agents such as rapamycin, sirolimus, tacrolimus, everolimus, cyclosporin A; anti-inflammatory cytokines such as interleukin-10.

The anti-inflammatory potential of agents can be assessed by studying their inhibition of cyclooxygenase-1 and cyclooxygenase-2 (Everts et al., 2000. Clin. Rheumatol. 19: 331-343), their inhibition of phospholipase activity and prostaglandine release (Sampey et al., *Mediators Inflamm.* 9:125-132, 2000), their inhibition of tumor necrosis factor-alpha (TNF-α) synthesis and secretion (Joyce et al., *Inflamm Res.* 46:447-451, 1997), their inhibition of vasodilation and permeability of the microcirculation (Perratti and Ahluwalia, 2000 Microcirculation 7: 147-161), their inhibition of toluene di-isocyanate-induced mast cell proliferation and degranulation, of anti-CD3-induced T-lymphocyte proliferation, of TNF-α-induced cell adhesion molecule expression, of oedema formation, of interleukin-5 (IL-5)-induced blood eosinophilia, of IL-5- or platelet activating factor- stimulated pulmonary eosinophilia, (Johnson, 1995 Allergy 50: 11-14), with neutrophil activation assays (Jackson et al., 1997 Immunology 90: 502-510), with cytokine gene expression assays (White et al., 1998 Cancer Immunol. Immunother. 46: 104-112).

Anti-platelet agents

Hemostasis is the spontaneous arrest of bleeding from a damaged blood vessel. The normal vascular endothelium is not thrombogenic and circulating blood platelets and clotting factors do not adhere to it. However, within seconds of damage to a blood vessel, platelets adhere to the site of injury. As platelets become activated, they secrete agents such as ADP and prostaglandins that enhance recruitment and adherence of other platelets. The resulting growing thrombus of aggregated platelets reduces blood flow and triggers fibrin formation. The fibrin network reinforces the initial platelet plug thus ensuring long-term hemostasis. At a later stage, platelets release growth factors such as platelet-derived growth factor that promote healing of the damage blood vessel.

Anti-platelet agents are compounds that interfere with platelet activation, adhesion or secretion and thus inhibit thrombus formation. Examples of anti-platelet agents include but are not limited to, aspirin (Awtry, 2000, Circulation, 101: 1206-1218), ADP receptor antagonists such as clopidogrel, ticlopidine and their active metabolites (Coukell and Markham, 1997 Drugs 54: 745-750; Muller et al., 2000 Circulation 101: 590-593; Bertrand et al., 2000 Circulation 102: 624-629; Quinn and Fitzgerald, 1999 Circulation 100: 1667-1672), serotonin receptor antagonists (Herbert et al., 1993 Thromb. Haemostas. 69: 262-2670), platelet glycoprotein receptor antagonists such as abciximab, tirofiban, eptifibatide, lamifiban, orbofiban, roxifiban, sibrafiban, lefradafiban, xemilofiban and their active metabolites (Dobesh and Latham, 1998 Pharmacotherapy 18: 663-685; Madan et al., 1998 Circulation 98: 2629-2635), statins such as pravastatin, fluvastatin, simvastatin, lovastatin (Igarashi et al., 1997 British Journal of Pharmacology 120: 1172-1178), cAMP phosphodiesterase inhibitors such as cilostazol (Kimura et al., 1985 Drug Res. 35: 1144-1149); nitric oxyde donors such as molsidomine, linsidomine, L-arginine (), alpha-adrenergic antagonists such as dihydrogeneted ergopeptines, phentolamine, and yohimbin.

The antiplatelet activity of agents can be assayed by monitoring *in vitro* platelet aggregation after activation by agonists using turbidimetry or radiolabeled platelets. *In vivo* quantification of platelet aggregation can be performed with radiolabeled platelets in models of arterio-venous shunts, stent placement and graft implantation. *In vivo* antiplatelet activity can also be assessed by monitoring arterial temperature distal to thrombus formation and by determining bleeding time. (Hebert et

al., 1998 Thromb. Haemost. 80: 512-518; Hebert et al., 1993 Arteriosclerosis and Thrombosis 13: 1171-1179; Harker et al., 1998 Circulation 98: 2461-2469; Yao et al., 1993 Trans. Associa. AU Physicians 106: 110-119).

Anticoagulants

Blood coagulates by the transformation of soluble fibrinogen into insoluble fibrin. More than a dozen circulating proteins interact in a cascading series of proteolytic reactions. At each step, an inactive clotting factor undergoes proteolytic cleavage and become an active protease. This protease activates the next clotting factor. The end product of the coagulation cascade is the formation of a solid fibrin clot.

Anticoagulants are agents that interfere with the coagulation cascade and inhibit the formation of fibrin. Examples of anticoagulants include, but are not limited to, warfarin and coumarin anticoagulants, tissue factor pathway inhibitor, active-site inactivated factor VIIa (DEGR-VIIa), tick anticoagulant peptide, antithrombin agents such as heparin, low-molecular-weight-heparin, hirudin, bivalirudin (Jang et al., 1995 Circulation 92: 3041-3050), retinoids such as all-trans-retinoic acid.

The anticoagulation activity of agents can be assayed by measuring the activated partial thromboplastin time and the prothrombin time (Freund et al., 1993 Thrombosis and Hemostasis 69: 515-521; Jang et al., 1995 Circulation 92: 3041-3050).

Fibrinolytic agents

Fibrinolysis is a naturally occurring process that removes unneeded clots once healing has occurred. The critical step in this system is the transformation of plasminogen into plasmin, a protein-digesting enzyme. Plasmin dissolves thrombus by lysing fibrin.

Fibrinolytic drugs promote the formation of plasmin. Examples of fibrinolytic agents include, but are not limited to, tissue plasminogen activator, urokinase, streptokinase, staphylokinase, anistreplase, reteplase, lanoteplase (Valji, 2000 JVIR 11: 411-420) retinoids such as all-trans-retinoic acid.

Fibrinolysis activity of agents can be assayed by monitoring the dissolution of thrombus labeled with radioactive fibrin (Herbert et al., 1993 Thrombosis and Haemostasis 69: 268-271).

Cell Cycle Inhibitors.

Briefly, a wide variety of cell cycle inhibitory agents can be utilized, either with or without a carrier (*e.g.,* a polymer or ointment or vector), in order to treat or prevent a hyperproliferative disease. Representative examples of such agents include taxanes (*e.g.,* paclitaxel (discussed in more detail below) and docetaxel) (Schiff *et al.*, *Nature 277*:665-667, 1979; Long and Fairchild, *Cancer Research 54*:4355-4361, 1994; Ringel and Horwitz, *J. Nat'l Cancer Inst. 83*(4):288-291, 1991; Pazdur *et al.*, *Cancer Treat. Rev. 19*(40):351-386, 1993), Etanidazole, Nimorazole (B.A. Chabner and D.L. Longo. Cancer Chemotherapy and Biotherapy – Principles and Practice. Lippincott-Raven Publishers, New York, 1996, p.554), perfluorochemicals with hyperbaric oxygen, transfusion, erythropoietin, BW12C, nicotinamide, hydralazine, BSO, WR-2721, IudR, DUdR, etanidazole, WR-2721, BSO, mono-substituted keto-aldehyde compounds (L.G. Egyud. Keto-aldehyde-amine addition products and method of making same. U.S. Patent No. 4,066,650, Jan 3, 1978), nitroimidazole (K.C. Agrawal and M. Sakaguchi. Nitroimidazole radiosensitizers for Hypoxic tumor cells and compositions thereof. U.S. Patent No. 4,462,992, Jul. 31, 1984), 5-substituted-4-nitroimidazoles (Adams *et al.*, *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 40*(2):153-61, 1981), SR-2508 (Brown *et al.*, *Int. J. Radiat. Oncol., Biol. Phys. 7*(6):695-703, 1981), 2H-isoindolediones (J.A. Myers, 2H-Isoindolediones, their synthesis and use as radiosensitizers. Patent 4,494,547, Jan. 22, 1985), chiral [[(2-bromoethyl)-amino]methyl]-nitro-1H-imidazole-1-ethanol (V.G. Beylin, *et al.*, Process for preparing chiral [[(2-bromoethyl)-amino]methyl]-nitro-1H-imidazole-1-ethanol and related compounds. U.S. Patent No. 5,543,527, Aug. 6, 1996; U.S. Patent No. 4,797,397; Jan. 10, 1989; U.S. Patent No. 5,342,959, Aug. 30, 1994), nitroaniline derivatives (W.A. Denny, *et al.* Nitroaniline derivatives and their use as anti-tumor agents. U.S. Patent No. 5,571,845, Nov. 5, 1996), DNA-affinic hypoxia selective cytotoxins (M.V. Papadopoulou-Rosenzweig. DNA-affinic hypoxia selective cytotoxins. U.S. Patent No. 5,602,142, Feb. 11, 1997), halogenated DNA ligand (R.F. Martin. Halogenated DNA ligand radiosensitizers for cancer therapy. U.S. Patent No. 5,641,764, Jun 24, 1997), 1,2,4 benzotriazine oxides (W.W. Lee *et al.* 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents. U.S. Patent No. 5,616,584, Apr. 1, 1997; U.S. Patent No. 5,624,925, Apr. 29, 1997; Process for Preparing 1,2,4 Benzotriazine oxides. U.S. Patent No. 5,175,287, Dec. 29, 1992), nitric

oxide (J.B. Mitchell *et al.*, Use of Nitric oxide releasing compounds as hypoxic cell radiation sensitizers. U.S. Patent No. 5,650,442, Jul. 22, 1997), 2-nitroimidazole derivatives (M.J. Suto *et al.* 2-Nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells. U.S. Patent No. 4,797,397, Jan. 10, 1989; T. Suzuki. 2-Nitroimidazole derivative, production thereof, and radiosensitizer containing the same as active ingredient. U.S. Patent No. 5,270,330, Dec. 14, 1993; T. Suzuki *et al.* 2-Nitroimidazole derivative, production thereof, and radiosensitizer containing the same as active ingredient. U.S. Patent No. 5,270,330, Dec 14, 1993; T. Suzuki. 2-Nitroimidazole derivative, production thereof and radiosensitizer containing the same as active ingredient; Patent EP 0 513 351 B1, Jan. 24, 1991), fluorine-containing nitroazole derivatives (T. Kagiya. Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same. U.S. Patent No. 4,927,941, May 22, 1990), copper (M.J. Abrams. Copper Radiosensitizers. U.S. Patent No. 5,100,885, Mar. 31, 1992), combination modality cancer therapy (D.H. Picker *et al.* Combination modality cancer therapy. U.S. Patent No. 4,681,091, Jul. 21, 1987). 5-CldC or (d)H_4U or 5-halo-2'-halo-2'-deoxy-cytidine or -uridine derivatives (S.B. Greer. Method and Materials for sensitizing neoplastic tissue to radiation. U.S. Patent No. 4,894,364 Jan. 16, 1990), platinum complexes (K.A. Skov. Platinum Complexes with one radiosensitizing ligand. U.S. Patent No. 4,921,963. May 1, 1990; K.A. Skov. Platinum Complexes with one radiosensitizing ligand. Patent EP 0 287 317 A3), fluorine-containing nitroazole (T. Kagiya, *et al.* Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same. U.S. Patent No. 4,927,941. May 22,1990), benzamide (W.W. Lee. Substituted Benzamide Radiosensitizers. U.S. Patent No. 5,032,617, Jul. 16, 1991), autobiotics (L.G. Egyud. Autobiotics and their use in eliminating nonself cells *in vivo*. U.S. Patent No. 5,147,652. Sep. 15,1992), benzamide and nicotinamide (W.W. Lee *et al.* Benzamide and Nictoinamide Radiosensitizers. U.S. Patent No. 5,215,738, Jun 1 1993), acridine-intercalator (M. Papadopoulou-Rosenzweig. Acridine Intercalator based hypoxia selective cytotoxins. U.S. Patent No. 5,294,715, Mar. 15,1994), fluorine-containing nitroimidazole (T. Kagiya *et al.* Fluorine containing nitroimidazole compounds. U.S. Patent No. 5,304,654, Apr. 19, 1994), hydroxylated texaphyrins (J.L. Sessler *et al.* Hydroxylated texaphrins. U.S. Patent No. 5,457,183, Oct. 10, 1995), hydroxylated compound derivative (T. Suzuki *et al.* Heterocyclic compound derivative, production thereof and radiosensitizer and antiviral agent containing said derivative as

active ingredient. Publication Number 011106775 A (Japan), Oct. 22,1987; T. Suzuki *et al.* Heterocyclic compound derivative, production thereof and radiosensitizer, antiviral agent and anti cancer agent containing said derivative as active ingredient. Publication Number 01139596 A (Japan), Nov. 25, 1987; S. Sakaguchi *et al.* Heterocyclic compound derivative, its production and radiosensitizer containing said derivative as active ingredient; Publication Number 63170375 A (Japan), Jan. 7, 1987), fluorine containing 3-nitro-1,2,4-triazole (T. Kagitani *et al.* Novel fluorine-containing 3-nitro-1,2,4-triazole and radiosensitizer containing same compound. Publication Number 02076861 A (Japan), Mar. 31, 1988), 5-thiotretrazole derivative or its salt (E. Kano *et al.* Radiosensitizer for Hypoxic cell. Publication Number 61010511 A (Japan), Jun. 26, 1984), Nitrothiazole (T .Kagitani *et al.* Radiation-sensitizing agent. Publication Number 61167616 A (Japan) Jan. 22, 1985), imidazole derivatives (S. Inayma *et al.* Imidazole derivative. Publication Number 6203767 A (Japan) Aug. 1,1985; Publication Number 62030768 A (Japan) Aug. 1, 1985; Publication Number 62030777 A (Japan) Aug. 1, 1985), 4-nitro-1,2,3-triazole (T. Kagitani *et al.* Radiosensitizer. Publication Number 62039525 A (Japan), Aug. 15, 1985), 3-nitro-1,2,4-triazole (T. Kagitani *et al.* Radiosensitizer. Publication Number 62138427 A (Japan), Dec. 12, 1985), Carcinostatic action regulator (H. Amagase. Carcinostatic action regulator. Publication Number 63099017 A (Japan), Nov. 21, 1986), 4,5-dinitroimidazole derivative (S. Inayama. 4,5-Dinitroimidazole derivative. Publication Number 63310873 A (Japan) Jun. 9, 1987), nitrotriazole Compound (T. Kagitanil. Nitrotriazole Compound. Publication Number 07149737 A (Japan) Jun. 22, 1993), cisplatin, doxorubin, misonidazole, mitomycin, tiripazamine, nitrosourea, mercaptopurine, methotrexate, flurouracil, bleomycin, vincristine, carboplatin, epirubicin, doxorubicin, cyclophosphamide, vindesine, etoposide (I.F. Tannock. Review Article: Treatment of Cancer with Radiation and Drugs. *Journal of Clinical Oncology 14*(12):3156-3174, 1996), camptothecin (Ewend M.G. *et al.* Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. *Cancer Research 56*(22):5217-5223, 1996) and paclitaxel (Tishler R.B. *et al.* Taxol: a novel radiation sensitizer. *International Journal of Radiation Oncology and Biological Physics 22*(3):613-617, 1992).

A number of the above-mentioned cell cycle inhibitors also have a wide variety of analogues and derivatives, including, but not limited to, cisplatin,

cyclophosphamide, misonidazole, tiripazamine, nitrosourea, mercaptopurine, methotrexate, flurouracil, epirubicin, doxorubicin, vindesine and etoposide. Analogues and derivatives include $(CPA)_2Pt[DOLYM]$ and (DACH)Pt[DOLYM] cisplatin (Choi *et al.*, *Arch. Pharmacal Res.* *22*(2):151-156, 1999), Cis-[$PtCl_2$(4,7-H-5-methyl-7-oxo]1,2,4[triazolo[1,5-a]pyrimidine)$_2$] (Navarro *et al.*, *J. Med. Chem.* *41*(3):332-338, 1998), [Pt(cis-1,4-DACH)(trans-Cl_2)(CBDCA)] • ½MeOH cisplatin (Shamsuddin *et al.*, *Inorg. Chem.* *36*(25):5969-5971, 1997), 4-pyridoxate diammine hydroxy platinum (Tokunaga *et al.*, *Pharm. Sci.* *3*(7):353-356, 1997), Pt(II) • • • Pt(II) (Pt_2[NHCHN(C(CH_2)(CH_3))]$_4$) (Navarro *et al.*, *Inorg. Chem.* *35*(26):7829-7835, 1996), 254-S cisplatin analogue (Koga *et al.*, *Neurol. Res.* *18*(3):244-247, 1996), *o*-phenylenediamine ligand bearing cisplatin analogues (Koeckerbauer & Bednarski, *J. Inorg. Biochem.* *62*(4):281-298, 1996), trans, cis-[Pt(OAc)$_2$$I_2$(en)] (Kratochwil *et al.*, *J. Med. Chem.* *39*(13):2499-2507, 1996), estrogenic 1,2-diarylethylenediamine ligand (with sulfur-containing amino acids and glutathione) bearing cisplatin analogues (Bednarski, *J. Inorg. Biochem.* *62*(1):75, 1996), cis-1,4-diaminocyclohexane cisplatin analogues (Shamsuddin *et al.*, *J. Inorg. Biochem.* *61*(4):291-301, 1996), 5' orientational isomer of cis-[Pt(NH_3)(4-aminoTEMP-O){d(GpG)}] (Dunham & Lippard, *J. Am. Chem. Soc.* *117*(43):10702-12, 1995), chelating diamine-bearing cisplatin analogues (Koeckerbauer & Bednarski, *J. Pharm. Sci.* *84*(7):819-23, 1995), 1,2-diarylethyleneamine ligand-bearing cisplatin analogues (Otto *et al.*, *J. Cancer Res. Clin. Oncol.* *121*(1):31-8, 1995), (ethylenediamine)platinum(II) complexes (Pasini *et al.*, *J. Chem. Soc., Dalton Trans.* *4*:579-85, 1995), CI-973 cisplatin analogue (Yang *et al.*, *Int. J. Oncol.* *5*(3):597-602, 1994), cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutanedicarbosylato(2R)-2-methyl-1,4-butanediam-mineplatinum(II) and cis-diammine(glycolato)platinum (Claycamp & Zimbrick, *J. Inorg. Biochem.* 26(4):257-67, 1986; Fan *et al.*, *Cancer Res.* *48*(11):3135-9, 1988; Heiger-Bernays *et al.*, *Biochemistry* *29*(36):8461-6, 1990; Kikkawa *et al.*, *J. Exp. Clin. Cancer Res.* *12*(4):233-40, 1993; Murray *et al.*, *Biochemistry* *31*(47):11812-17, 1992; Takahashi *et al.*, *Cancer Chemother. Pharmacol.* *33*(1):31-5, 1993), cis-amine-cyclohexylamine-dichloroplatinum(II) (Yoshida *et al.*, *Biochem. Pharmacol.* *48*(4):793-9, 1994), gem-diphosphonate cisplatin analogues (FR 2683529), (meso-1,2-bis(2,6-dichloro-4-hydroxyplenyl)ethylenediamine) dichloroplatinum(II) (Bednarski *et al.*, *J. Med. Chem.*

35(23):4479-85, 1992), cisplatin analogues containing a tethered dansyl group (Hartwig *et al.*, *J. Am. Chem. Soc. 114*(21):8292-3, 1992), platinum(II) polyamines (Siegmann *et al.*, *Inorg. Met.-Containing Polym. Mater., (Proc. Am. Chem. Soc. Int. Symp.)*, 335-61, 1990), cis-(3H)dichloro(ethylenediamine)platinum(II) (Eastman, *Anal. Biochem. 197*(2):311-15, 1991), trans-diamminedichloroplatinum(II) and cis-($Pt(NH_3)_2(N_3$-cytosine)Cl) (Bellon & Lippard, *Biophys. Chem. 35*(2-3):179-88, 1990), 3H-cis-1,2-diaminocyclohexanedichloroplatinum(II) and 3H-cis-1,2-diaminocyclohexane-malonatoplatinum (II) (Oswald *et al.*, *Res. Commun. Chem. Pathol. Pharmacol. 64*(1):41-58, 1989), diaminocarboxylatoplatinum (EPA 296321), trans-(D,1)-1,2-diaminocyclohexane carrier ligand-bearing platinum analogues (Wyrick & Chaney, *J. Labelled Compd. Radiopharm. 25*(4):349-57, 1988), aminoalkylaminoanthraquinone-derived cisplatin analogues (Kitov *et al.*, *Eur. J. Med. Chem. 23*(4):381-3, 1988), spiroplatin, carboplatin, iproplatin and JM40 platinum analogues (Schroyen *et al.*, *Eur. J. Cancer Clin. Oncol. 24*(8):1309-12, 1988), bidentate tertiary diamine-containing cisplatinum derivatives (Orbell *et al.*, *Inorg. Chim. Acta 152*(2):125-34, 1988), platinum(II), platinum(IV) (Liu & Wang, *Shandong Yike Daxue Xuebao 24*(1):35-41, 1986), cis-diammine(1,1-cyclobutanedicarboxylato-)platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40) (Begg *et al.*, *Radiother. Oncol. 9*(2):157-65, 1987), JM8 and JM9 cisplatin analogues (Harstrick *et al.*, *Int. J. Androl. 10*(1); 139-45, 1987), (NPr4)2((PtCL4).cis-(PtCl2-(NH2Me)2)) (Brammer *et al.*, *J. Chem. Soc., Chem. Commun. 6*:443-5, 1987), aliphatic tricarboxylic acid platinum complexes (EPA 185225), cis-dichloro(amino acid)(tert-butylamine)platinum(II) complexes (Pasini & Bersanetti, *Inorg. Chim. Acta 107*(4):259-67, 1985); 4-hydroperoxycylcophosphamide (Ballard *et al.*, *Cancer Chemother. Pharmacol. 26*(6):397-402, 1990), acyclouridine cyclophosphamide derivatives (Zakerinia *et al.*, *Helv. Chim. Acta 73*(4):912-15, 1990), 1,3,2-dioxa- and –oxazaphosphorinane cyclophosphamide analogues (Yang *et al.*, *Tetrahedron 44*(20):6305-14, 1988), C5-substituted cyclophosphamide analogues (Spada, University of Rhode Island Dissertation, 1987), tetrahydrooxazine cyclophosphamide analogues (Valente, University of Rochester Dissertation, 1988), phenyl ketone cyclophosphamide analogues (Hales *et al.*, *Teratology 39*(1):31-7, 1989), phenylketophosphamide cyclophosphamide analogues (Ludeman *et al.*, *J. Med. Chem. 29*(5):716-27, 1986), ASTA Z-7557 cyclophosphamide analogues (Evans *et al.*, *Int. J. Cancer 34*(6):883-90,

1984), 3-(1-oxy-2,2,6,6-tetramethyl-4-piperidinyl)cyclophosphamide (Tsui *et al.*, *J. Med. Chem.* *25*(9):1106-10, 1982), 2-oxobis(2-β-chloroethylamino)-4-,6-dimethyl-1,3,2-oxazaphosphorinane cyclophosphamide (Carpenter *et al.*, *Phosphorus Sulfur* *12*(3):287-93, 1982), 5-fluoro- and 5-chlorocyclophosphamide (Foster *et al.*, *J. Med. Chem.* *24*(12):1399-403, 1981), cis- and trans-4-phenylcyclophosphamide (Boyd *et al.*, *J. Med. Chem.* *23*(4):372-5, 1980), 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide (Ludeman *et al.*, *J. Med. Chem.* *22*(2):151-8, 1979), 4-ethoxycarbonyl cyclophosphamide analogues (Foster, *J. Pharm. Sci.* *67*(5):709-10, 1978), arylaminotetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide cyclophosphamide analogues (Hamacher, *Arch. Pharm. (Weinheim, Ger.)* *310*(5):J,428-34, 1977), NSC-26271 cyclophosphamide analogues (Montgomery & Struck, *Cancer Treat. Rep.* *60*(4):J381-93, 1976), benzo annulated cyclophosphamide analogues (Ludeman & Zon, *J. Med. Chem.* *18*(12):J1251-3, 1975), 6-trifluoromethylcyclophosphamide (Farmer & Cox, *J. Med. Chem.* *18*(11):J1106-10, 1975), 4-methylcyclophosphamide and 6-methycyclophosphamide analogues (Cox *et al.*, *Biochem. Pharmacol.* *24*(5):J599-606, 1975); FCE 23762 doxorubicin derivative (Quaglia *et al.*, *J. Liq. Chromatogr.* *17*(18):3911-3923, 1994), annamycin (Zou *et al.*, *J. Pharm. Sci.* *82*(11):1151-1154, 1993), ruboxyl (Rapoport *et al.*, *J. Controlled Release* *58*(2):153-162, 1999), anthracycline disaccharide doxorubicin analogue (Pratesi *et al.*, *Clin. Cancer Res.* *4*(11):2833-2839, 1998), N-(trifluoroacetyl)doxorubicin and 4'-O-acetyl-N-(trifluoroacetyl)doxorubicin (Berube & Lepage, *Synth. Commun.* *28*(6):1109-1116, 1998), 2-pyrrolinodoxorubicin (Nagy *et al.*, *Proc. Nat'l Acad. Sci. U.S.A.* *95*(4):1794-1799, 1998), disaccharide doxorubicin analogues (Arcamone *et al.*, *J. Nat'l Cancer Inst.* *89*(16):1217-1223, 1997), 4-demethoxy-7-O-[2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-α-L-lyxo-hexopyranosyl)-α-L-lyxo-hexopyranosyl]adriamicinone doxorubicin disaccharide analog (Monteagudo *et al.*, *Carbohydr. Res.* *300*(1):11-16, 1997), 2-pyrrolinodoxorubicin (Nagy *et al.*, *Proc. Nat'l Acad. Sci. U. S. A.* *94*(2):652-656, 1997), morpholinyl doxorubicin analogues (Duran *et al.*, *Cancer Chemother. Pharmacol.* *38*(3):210-216, 1996), enaminomalonyl-β-alanine doxorubicin derivatives (Seitz *et al.*, *Tetrahedron Lett.* *36*(9):1413-16, 1995), cephalosporin doxorubicin derivatives (Vrudhula *et al.*, *J. Med. Chem.* *38*(8):1380-5, 1995), hydroxyrubicin (Solary *et al.*, *Int. J. Cancer* *58*(1):85-94, 1994), methoxymorpholino doxorubicin derivative (Kuhl *et al.*, *Cancer Chemother. Pharmacol.* *33*(1):10-16, 1993), (6-maleimidocaproyl)hydrazone

doxorubicin derivative (Willner *et al.*, *Bioconjugate Chem.* *4*(6):521-7, 1993), N-(5,5-diacetoxypent-1-yl) doxorubicin (Cherif & Farquhar, *J. Med. Chem.* *35*(17):3208-14, 1992), FCE 23762 methoxymorpholinyl doxorubicin derivative (Ripamonti *et al.*, *Br. J. Cancer* *65*(5):703-7, 1992), N-hydroxysuccinimide ester doxorubicin derivatives (Demant *et al.*, *Biochim. Biophys. Acta* *1118*(1):83-90, 1991), polydeoxynucleotide doxorubicin derivatives (Ruggiero *et al.*, *Biochim. Biophys. Acta* *1129*(3):294-302, 1991), morpholinyl doxorubicin derivatives (EPA 434960), mitoxantrone doxorubicin analogue (Krapcho *et al.*, *J. Med. Chem.* *34*(8):2373-80. 1991), AD198 doxorubicin analogue (Traganos *et al.*, *Cancer Res.* *51*(14):3682-9, 1991), 4-demethoxy-3'-N-trifluoroacetyldoxorubicin (Horton *et al.*, *Drug Des. Delivery* *6*(2):123-9, 1990), 4'-epidoxorubicin (Drzewoski *et al.*, *Pol. J. Pharmacol. Pharm.* *40*(2):159-65, 1988; Weenen *et al.*, *Eur. J. Cancer Clin. Oncol.* *20*(7):919-26, 1984), alkylating cyanomorpholino doxorubicin derivative (Scudder *et al.*, *J. Nat'l Cancer Inst.* *80*(16):1294-8, 1988), deoxydihydroiodooxorubicin (EPA 275966), adriblastin (Kalishevskaya *et al.*, *Vestn. Mosk. Univ.*, *16*(Biol. 1):21-7, 1988), 4'-deoxydoxorubicin (Schoelzel *et al.*, *Leuk. Res.* *10*(12):1455-9, 1986), 4-demethyoxy-4'-o-methyldoxorubicin (Giuliani *et al.*, *Proc. Int. Congr. Chemother.* *16*:285-70-285-77, 1983), 3'-deamino-3'-hydroxydoxorubicin (Horton *et al.*, *J. Antibiot.* *37*(8):853-8, 1984), 4-demethyoxy doxorubicin analogues (Barbieri *et al.*, *Drugs Exp. Clin. Res.* *10*(2):85-90, 1984), N-L-leucyl doxorubicin derivatives (Trouet *et al.*, Anthracyclines (*Proc. Int. Symp. Tumor Pharmacother.*), 179-81, 1983), 3'-deamino-3'-(4-methoxy-1-piperidinyl) doxorubicin derivatives (4,314,054), 3'-deamino-3'-(4-mortholinyl) doxorubicin derivatives (4,301,277), 4'-deoxydoxorubicin and 4'-*o*-methyldoxorubicin (Giuliani *et al.*, *Int. J. Cancer* *27*(1):5-13, 1981), aglycone doxorubicin derivatives (Chan & Watson, *J. Pharm. Sci.* *67*(12):1748-52, 1978), SM 5887 (*Pharma Japan* *1468*:20, 1995), MX-2 (*Pharma Japan* *1420*:19, 1994), 4'-deoxy-13(S)-dihydro-4'-iododoxorubicin (EP 275966), morpholinyl doxorubicin derivatives (EPA 434960), 3'-deamino-3'-(4-methoxy-1-piperidinyl) doxorubicin derivatives (4,314,054), doxorubicin-14-valerate, morpholinodoxorubicin (5,004,606), 3'-deamino-3'-(3"-cyano-4"-morpholinyl doxorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-13-dihydoxorubicin; (3'-deamino-3'-(3"-cyano-4"-morpholinyl) daunorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-3-dihydrodaunorubicin; and 3'-deamino-3'-(4"-morpholinyl-5-iminodoxorubicin and derivatives (4,585,859), 3'-deamino-3'-(4-

methoxy-1-piperidinyl) doxorubicin derivatives (4,314,054) and 3-deamino-3-(4-morpholinyl) doxorubicin derivatives (4,301,277); 4,5-dimethylmisonidazole (Born *et al.*, *Biochem. Pharmacol.* *43*(6):1337-44, 1992), azo and azoxy misonidazole derivatives (Gattavecchia & Tonelli, *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* *45*(5):469-77, 1984); RB90740 (Wardman *et al.*, *Br. J. Cancer, 74 Suppl.* (27):S70-S74, 1996); 6-bromo and 6-chloro-2,3-dihydro-1,4-benzothiazines nitrosourea derivatives (Rai *et al.*, *Heterocycl. Commun.* *2*(6):587-592, 1996), diamino acid nitrosourea derivatives (Dulude *et al.*, *Bioorg. Med. Chem. Lett.* *4*(22):2697-700, 1994; Dulude *et al.*, *Bioorg. Med. Chem.* *3*(2):151-60, 1995), amino acid nitrosourea derivatives (Zheleva *et al.*, *Pharmazie* *50*(1):25-6, 1995), 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin nitrosourea derivatives (Miyahara *et al.*, *Heterocycles* *39*(1):361-9, 1994), ACNU (Matsunaga *et al.*, *Immunopharmacology* *23*(3):199-204, 1992), tertiary phosphine oxide nitrosourea derivatives (Guguva *et al.*, *Pharmazie* *46*(8):603, 1991), sulfamerizine and sulfamethizole nitrosourea derivatives (Chiang *et al.*, *Zhonghua Yaozue Zazhi* *43*(5):401-6, 1991), thymidine nitrosourea analogues (Zhang *et al.*, *Cancer Commun.* *3*(4):119-26, 1991), 1,3-bis(2-chloroethyl)-1-nitrosourea (August *et al.*, *Cancer Res.* *51*(6):1586-90, 1991), 2,2,6,6-tetramethyl-1-oxopiperidiunium nitrosourea derivatives (U.S.S.R. 1261253), 2- and 4-deoxy sugar nitrosourea derivatives (4,902,791), nitroxyl nitrosourea derivatives (U.S.S.R. 1336489), fotemustine (Boutin *et al.*, *Eur. J. Cancer Clin. Oncol.* *25*(9):1311-16, 1989), pyrimidine (II) nitrosourea derivatives (Wei *et al.*, *Chung-hua Yao Hsueh Tsa Chih* *41*(1):19-26, 1989), CGP 6809 (Schieweck *et al.*, *Cancer Chemother. Pharmacol.* *23*(6):341-7, 1989), B-3839 (Prajda *et al.*, *In Vivo* *2*(2):151-4, 1988), 5-halogenocytosine nitrosourea derivatives (Chiang & Tseng, *T'ai-wan Yao Hsueh Tsa Chih* *38*(1):37-43, 1986), 1-(2-chloroethyl)-3-isobutyl-3-(β-maltosyl)-1-nitrosourea (Fujimoto & Ogawa, *J. Pharmacobio-Dyn.* *10*(7):341-5, 1987), sulfur-containing nitrosoureas (Tang *et al.*, Yaoxue *Xuebao* *21*(7):502-9, 1986), sucrose, 6-((((2-chloroethyl)nitrosoamino-)carbonyl)amino)-6-deoxysucrose (NS-1C) and 6'-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6'-deoxysucrose (NS-1D) nitrosourea derivatives (Tanoh *et al.*, *Chemotherapy (Tokyo)* *33*(11):969-77, 1985), CNCC, RFCNU and chlorozotocin (Mena *et al.*, *Chemotherapy (Basel)* *32*(2):131-7, 1986), CNUA (Edanami *et al.*, *Chemotherapy (Tokyo)* *33*(5):455-61, 1985), 1-(2-chloroethyl)-3-isobutyl-3-(β-maltosyl)-1-nitrosourea (Fujimoto & Ogawa, *Jpn. J. Cancer Res. (Gann)*

76(7):651-6, 1985), choline-like nitrosoalkylureas (Belyaev *et al.*, *Izv. Akad. NAUK SSSR, Ser. Khim. 3*:553-7, 1985), sucrose nitrosourea derivatives (JP 84219300), sulfa drug nitrosourea analogues (Chiang *et al.*, *Proc. Nat'l Sci. Counc., Repub. China, Part A 8*(1):18-22, 1984), DONU (Asanuma *et al.*, *J. Jpn. Soc. Cancer Ther. 17*(8):2035-43, 1982), N,N'-bis (N-(2-chloroethyl)-N-nitrosocarbamoyl)cystamine (CNCC) (Blazsek *et al.*, *Toxicol. Appl. Pharmacol. 74*(2):250-7, 1984), dimethylnitrosourea (Krutova *et al.*, *Izv. Akad. NAUK SSSR, Ser. Biol. 3*:439-45, 1984), GANU (Sava & Giraldi, *Cancer Chemother. Pharmacol. 10*(3):167-9, 1983), CCNU (Capelli *et al.*, *Med., Biol., Environ. 11*(1):111-16, 1983), 5-aminomethyl-2'-deoxyuridine nitrosourea analogues (Shiau, *Shih Ta Hsueh Pao (Taipei) 27*:681-9, 1982), TA-077 (Fujimoto & Ogawa, *Cancer Chemother. Pharmacol. 9*(3):134-9, 1982), gentianose nitrosourea derivatives (JP 82 80396), CNCC, RFCNU, RPCNU AND chlorozotocin (CZT) (Marzin *et al.*, INSERM Symp., 19(Nitrosoureas Cancer Treat.):165-74, 1981), thiocolchicine nitrosourea analogues (George, *Shih Ta Hsueh Pao (Taipei) 25*:355-62, 1980), 2-chloroethyl-nitrosourea (Zeller & Eisenbrand, *Oncology 38*(1):39-42, 1981), ACNU, (1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride) (Shibuya *et al.*, *Gan To Kagaku Ryoho 7*(8):1393-401, 1980), N-deacetylmethyl thiocolchicine nitrosourea analogues (Lin *et al.*, *J. Med. Chem. 23*(12):1440-2, 1980), pyridine and piperidine nitrosourea derivatives (Crider *et al.*, *J. Med. Chem. 23*(8):848-51, 1980), methyl-CCNU (Zimber & Perk, *Refu. Vet. 35*(1):28, 1978), phensuzimide nitrosourea derivatives (Crider *et al.*, *J. Med. Chem. 23*(3):324-6, 1980), ergoline nitrosourea derivatives (Crider *et al.*, *J. Med. Chem. 22*(1):32-5, 1979), glucopyranose nitrosourea derivatives (JP 78 95917), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (Farmer *et al.*, *J. Med. Chem. 21*(6):514-20, 1978), 4-(3-(2-chloroethyl)-3-nitrosoureid-o)-cis-cyclohexanecarboxylic acid (Drewinko *et al.*, *Cancer Treat. Rep. 61*(8):J1513-18, 1977), RPCNU (ICIG 1163) (Larnicol *et al.*, *Biomedicine 26*(3):J176-81, 1977), IOB-252 (Sorodoc *et al.*, *Rev. Roum. Med. Virol. 28*(1):J55-61, 1977), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (Siebert & Eisenbrand, *Mutat. Res. 42*(1):J45-50, 1977), 1-tetrahydroxycyclopentyl-3-nitroso-3-(2-chloroethyl)-urea (4,039,578), d-1-1-(β-chloroethyl)-3-(2-oxo-3-hexahydroazepinyl)-1-nitrosourea (3,859,277) and gentianose nitrosourea derivatives (JP 57080396); 6-S-aminoacyloxymethyl mercaptopurine derivatives (Harada *et al.*, *Chem. Pharm. Bull. 43*(10):793-6, 1995), 6-mercaptopurine (6-MP) (Kashida *et al.*, *Biol. Pharm. Bull. 18*(11):1492-7, 1995), 7,8-

polymethyleneimidazo-1,3,2-diazaphosphorines (Nilov *et al.*, *Mendeleev Commun. 2*:67, 1995), azathioprine (Chifotides *et al.*, *J. Inorg. Biochem. 56*(4):249-64, 1994), methyl-D-glucopyranoside mercaptopurine derivatives (Da Silva *et al.*, *Eur. J. Med. Chem. 29*(2):149-52, 1994) and s-alkynyl mercaptopurine derivatives (Ratsino *et al.*, *Khim.-Farm. Zh. 15*(8):65-7, 1981); indoline ring and a modified ornithine or glutamic acid-bearing methotrexate derivatives (Matsuoka *et al.*, *Chem. Pharm. Bull. 45*(7):1146-1150, 1997), alkyl-substituted benzene ring C bearing methotrexate derivatives (Matsuoka *et al.*, *Chem. Pharm. Bull. 44*(12):2287-2293, 1996), benzoxazine or benzothiazine moiety-bearing methotrexate derivatives (Matsuoka *et al.*, *J. Med. Chem. 40*(1):105-111, 1997), 10-deazaaminopterin analogues (DeGraw *et al.*, *J. Med. Chem. 40*(3):370-376, 1997), 5-deazaaminopterin and 5,10-dideazaaminopterin methotrexate analogues (Piper *et al.*, *J. Med. Chem. 40*(3):377-384, 1997), indoline moiety-bearing methotrexate derivatives (Matsuoka *et al.*, *Chem. Pharm. Bull. 44*(7):1332-1337, 1996), lipophilic amide methotrexate derivatives (Pignatello *et al.*, World Meet. Pharm., Biopharm. Pharm. Technol., 563-4, 1995), L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid-containing methotrexate analogues (Hart *et al.*, *J. Med. Chem. 39*(1):56-65, 1996), methotrexate tetrahydroquinazoline analogue (Gangjee, *et al.*, *J. Heterocycl. Chem. 32*(1):243-8, 1995), N-(α-aminoacyl) methotrexate derivatives (Cheung *et al.*, *Pteridines 3*(1-2):101-2, 1992), biotin methotrexate derivatives (Fan *et al.*, *Pteridines 3*(1-2):131-2, 1992), D-glutamic acid or D-erythrou, threo-4-fluoroglutamic acid methotrexate analogues (McGuire *et al.*, *Biochem. Pharmacol. 42*(12):2400-3, 1991), β,γ-methano methotrexate analogues (Rosowsky *et al.*, *Pteridines 2*(3):133-9, 1991), 10-deazaaminopterin (10-EDAM) analogue (Braakhuis *et al.*, *Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.*, 1027-30, 1989), γ-tetrazole methotrexate analogue (Kalman *et al.*, *Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.*, 1154-7, 1989), N-(L-α-aminoacyl) methotrexate derivatives (Cheung *et al.*, *Heterocycles 28*(2):751-8, 1989), meta and ortho isomers of aminopterin (Rosowsky *et al.*, *J. Med. Chem. 32*(12):2582, 1989), hydroxymethylmethotrexate (DE 267495), γ-fluoromethotrexate (McGuire *et al.*, *Cancer Res. 49*(16):4517-25, 1989), polyglutamyl methotrexate derivatives (Kumar *et al.*, *Cancer Res. 46*(10):5020-3, 1986), gem-diphosphonate methotrexate analogues (WO 88/06158), α- and γ-substituted methotrexate analogues (Tsushima *et al.*,

Tetrahedron *44*(17):5375-87, 1988), 5-methyl-5-deaza methotrexate analogues (4,725,687), Nδ-acyl-Nα-(4-amino-4-deoxypteroyl)-L-ornithine derivatives (Rosowsky *et al.*, *J. Med. Chem.* *31*(7):1332-7, 1988), 8-deaza methotrexate analogues (Kuehl *et al.*, *Cancer Res.* *48*(6):1481-8, 1988), acivicin methotrexate analogue (Rosowsky *et al.*, *J. Med. Chem.* *30*(8):1463-9, 1987), polymeric platinol methotrexate derivative (Carraher *et al.*, *Polym. Sci. Technol. (Plenum), 35(Adv. Biomed. Polym.)*:311-24, 1987), methotrexate-γ-dimyristoylphophatidylethanolamine (Kinsky *et al.*, *Biochim. Biophys. Acta* *917*(2):211-18, 1987), methotrexate polyglutamate analogues (Rosowsky *et al.*, Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 985-8, 1986), poly-γ-glutamyl methotrexate derivatives (Kisliuk *et al.*, Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 989-92, 1986), deoxyuridylate methotrexate derivatives (Webber *et al.*, Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 659-62, 1986), iodoacetyl lysine methotrexate analogue (Delcamp *et al.*, Chem. Biol. Pteridines, Pteridines Folid Acid Deriv., Proc. Int. Symp. Pteridines Folid Acid Deriv.: Chem., Biol. Clin. Aspects: 807-9, 1986), 2,.omega.-diaminoalkanoid acid-containing methotrexate analogues (McGuire *et al.*, *Biochem. Pharmacol.* *35*(15):2607-13, 1986), polyglutamate methotrexate derivatives (Kamen & Winick, *Methods Enzymol.* *122*(Vitam. Coenzymes, Pt. G):339-46, 1986), 5-methyl-5-deaza analogues (Piper *et al.*, *J. Med. Chem.* *29*(6):1080-7, 1986), quinazoline methotrexate analogue (Mastropaolo *et al.*, *J. Med. Chem.* *29*(1):155-8, 1986), pyrazine methotrexate analogue (Lever & Vestal, *J. Heterocycl. Chem.* *22*(1):5-6, 1985), cysteic acid and homocysteic acid methotrexate analogues (4,490,529), γ-tert-butyl methotrexate esters (Rosowsky *et al.*, *J. Med. Chem.* *28*(5):660-7, 1985), fluorinated methotrexate analogues (Tsushima *et al.*, *Heterocycles* *23*(1):45-9, 1985), folate methotrexate analogue (Trombe, *J. Bacteriol.* *160*(3):849-53, 1984), phosphonoglutamic acid analogues (Sturtz & Guillamot, *Eur. J. Med. Chem.--Chim. Ther.* *19*(3):267-73, 1984), poly (L-lysine) methotrexate conjugates (Rosowsky *et al.*, *J. Med. Chem.* *27*(7):888-93, 1984), dilysine and trilysine methotrexate derivates (Forsch & Rosowsky, *J. Org. Chem.* *49*(7):1305-9, 1984), 7-hydroxymethotrexate (Fabre *et al.*, *Cancer Res.* *43*(10):4648-52, 1983), poly-γ-glutamyl methotrexate analogues (Piper & Montgomery, *Adv. Exp. Med. Biol., 163(Folyl Antifolyl Polyglutamates)*:95-100, 1983),

3',5'-dichloromethotrexate (Rosowsky & Yu, *J. Med. Chem. 26*(10):1448-52, 1983), diazoketone and chloromethylketone methotrexate analogues (Gangjee *et al.*, *J. Pharm. Sci. 71*(6):717-19, 1982), 10-propargylaminopterin and alkyl methotrexate homologs (Piper *et al.*, *J. Med. Chem. 25*(7):877-80, 1982), lectin derivatives of methotrexate (Lin *et al.*, *JNCI 66*(3):523-8, 1981), polyglutamate methotrexate derivatives (Galivan, *Mol. Pharmacol. 17*(1):105-10, 1980), halogentated methotrexate derivatives (Fox, *JNCI 58*(4):J955-8, 1977), 8-alkyl-7,8-dihydro analogues (Chaykovsky *et al.*, *J. Med. Chem. 20*(10):J1323-7, 1977), 7-methyl methotrexate derivatives and dichloromethotrexate (Rosowsky & Chen, *J. Med. Chem. 17*(12):J1308-11, 1974), lipophilic methotrexate derivatives and 3',5'-dichloromethotrexate (Rosowsky, *J. Med. Chem. 16*(10):J1190-3, 1973), deaza amethopterin analogues (Montgomery *et al.*, *Ann. N.Y. Acad. Sci. 186*:J227-34, 1971), MX068 (Pharma Japan, 1658:18, 1999) and cysteic acid and homocysteic acid methotrexate analogues (EPA 0142220); N3-alkylated analogues of 5-fluorouracil (Kozai *et al.*, *J. Chem. Soc., Perkin Trans. 1*(19):3145-3146, 1998), 5-fluorouracil derivatives with 1,4-oxaheteroepane moieties (Gomez *et al.*, *Tetrahedron 54*(43):13295-13312, 1998), 5-fluorouracil and nucleoside analogues (Li, *Anticancer Res. 17*(1A):21-27, 1997), cis- and trans-5-fluoro-5,6-dihydro-6-alkoxyuracil (Van der Wilt *et al.*, *Br. J. Cancer 68*(4):702-7, 1993), cyclopentane 5-fluorouracil analogues (Hronowski & Szarek, *Can. J. Chem. 70*(4):1162-9, 1992), A-OT-fluorouracil (Zhang *et al.*, *Zongguo Yiyao Gongye Zazhi 20*(11):513-15, 1989), N4-trimethoxybenzoyl-5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine (Miwa *et al.*, *Chem. Pharm. Bull. 38*(4):998-1003, 1990), 1-hexylcarbamoyl-5-fluorouracil (Hoshi *et al.*, *J. Pharmacobio-Dun. 3*(9):478-81, 1980; Maehara *et al.*, *Chemotherapy (Basel) 34*(6):484-9, 1988), B-3839 (Prajda *et al.*, *In Vivo 2*(2):151-4, 1988), uracil-1-(2-tetrahydrofuryl)-5-fluorouracil (Anai *et al.*, *Oncology 45*(3):144-7, 1988), 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-5-fluorouracil (Suzuko *et al.*, *Mol. Pharmacol. 31*(3):301-6, 1987), doxifluridine (Matuura *et al.*, *Oyo Yakuri 29*(5):803-31, 1985), 5'-deoxy-5-fluorouridine (Bollag & Hartmann, *Eur. J. Cancer 16*(4):427-32, 1980), 1-acetyl-3-O-toluyl-5-fluorouracil (Okada, *Hiroshima J. Med. Sci. 28*(1):49-66, 1979), 5-fluorouracil-m-formylbenzene-sulfonate (JP 55059173), N'-(2-furanidyl)-5-fluorouracil (JP 53149985) and 1-(2-tetrahydrofuryl)-5-fluorouracil (JP 52089680); 4'-epidoxorubicin (Lanius, Adv. Chemother. Gastrointest. Cancer, (Int. Symp.), 159-67, 1984); N-substituted deacetylvinblastine amide (vindesine) sulfates (Conrad *et al.*, *J. Med. Chem. 22*(4):391-

400, 1979); and Cu(II)-VP-16 (etoposide) complex (Tawa *et al.*, *Bioorg. Med. Chem.* *6*(7):1003-1008, 1998), pyrrolecarboxamidino-bearing etoposide analogues (Ji *et al.*, *Bioorg. Med. Chem. Lett.* *7*(5):607-612, 1997), 4β-amino etoposide analogues (Hu, University of North Carolina Dissertation, 1992), γ-lactone ring-modified arylamino etoposide analogues (Zhou *et al.*, *J. Med. Chem.* *37*(2):287-92, 1994), N-glucosyl etoposide analogue (Allevi *et al.*, *Tetrahedron Lett.* *34*(45):7313-16, 1993), etoposide A-ring analogues (Kadow *et al.*, *Bioorg. Med. Chem. Lett.* *2*(1):17-22, 1992), 4'-deshydroxy-4'-methyl etoposide (Saulnier *et al.*, *Bioorg. Med. Chem. Lett.* *2*(10):1213-18, 1992), pendulum ring etoposide analogues (Sinha *et al.*, *Eur. J. Cancer* *26*(5):590-3, 1990) and E-ring desoxy etoposide analogues (Saulnier *et al.*, *J. Med. Chem.* *32*(7):1418-20, 1989).

Within one preferred embodiment of the invention, the cell cycle inhibitor is taxane such as paclitaxel. Briefly, taxanes are compounds which disrupts mitosis (M-phase) by binding to tubulin to form abnormal mitotic spindles or an analogue or derivative thereof. Paclitaxel, the most recognized member of the taxane family is a highly derivatized diterpenoid (Wani *et al.*, *J. Am. Chem. Soc.* *93*:2325, 1971) which has been obtained from the harvested and dried bark of *Taxus brevifolia* (Pacific Yew) and *Taxomyces Andreanae* and *Endophytic Fungus* of the Pacific Yew (Stierle *et al.*, *Science* *60*:214-216, 1993). "Paclitaxel" (which should be understood herein to include formulations, prodrugs, analogues and derivatives such as, for example, TAXOL®, TAXOTERE®, docetaxel, 10-desacetyl analogues of paclitaxel and 3'N-desbenzoyl-3'N-t-butoxy carbonyl analogues of paclitaxel) may be readily prepared utilizing techniques known to those skilled in the art (*see, e.g.*, Schiff *et al.*, *Nature* *277*:665-667, 1979; Long and Fairchild, *Cancer Research* *54*:4355-4361, 1994; Ringel and Horwitz, *J. Nat'l Cancer Inst.* *83*(4):288-291, 1991; Pazdur *et al.*, *Cancer Treat. Rev.* *19*(4):351-386, 1993; WO 94/07882; WO 94/07881; WO 94/07880; WO 94/07876; WO 93/23555; WO 93/10076; WO94/00156; WO 93/24476; EP 590267; WO 94/20089; U.S. Patent Nos. 5,294,637; 5,283,253; 5,279,949; 5,274,137; 5,202,448; 5,200,534; 5,229,529; 5,254,580; 5,412,092; 5,395,850; 5,380,751; 5,350,866; 4,857,653; 5,272,171; 5,411,984; 5,248,796; 5,248,796; 5,422,364; 5,300,638; 5,294,637; 5,362,831; 5,440,056; 4,814,470; 5,278,324; 5,352,805; 5,411,984; 5,059,699; 4,942,184; *Tetrahedron Letters* *35*(52):9709-9712, 1994; *J. Med. Chem.* *35*:4230-4237, 1992; *J. Med. Chem.* *34*:992-998, 1991; *J. Natural Prod.*


57(10):1404-1410, 1994; *J. Natural Prod. 57*(11):1580-1583, 1994; *J. Am. Chem. Soc. 110*:6558-6560, 1988), or obtained from a variety of commercial sources, including for example, Sigma Chemical Co., St. Louis, Missouri (T7402 – from *Taxus brevifolia*).

Representative examples of paclitaxel derivatives or analogues include 7-deoxy-docetaxol, 7,8-cyclopropataxanes, N-substituted 2-azetidones, 6,7-epoxy paclitaxels, 6,7-modified paclitaxels, 10-desacetoxytaxol, 10-deacetyltaxol (from 10-deacetylbaccatin III), phosphonooxy and carbonate derivatives of taxol, taxol 2',7-di(sodium 1,2-benzenedicarboxylate, 10-desacetoxy-11,12-dihydrotaxol-10,12(18)-diene derivatives, 10-desacetoxytaxol, Protaxol (2'-and/or 7-O-ester derivatives), (2'-and/or 7-O-carbonate derivatives), asymmetric synthesis of taxol side chain, fluoro taxols, 9-deoxotaxane, (13-acetyl-9-deoxobaccatine III, 9-deoxotaxol, 7-deoxy-9-deoxotaxol, 10-desacetoxy-7-deoxy-9-deoxotaxol, Derivatives containing hydrogen or acetyl group and a hydroxy and tert-butoxycarbonylamino, sulfonated 2'-acryloyltaxol and sulfonated 2'-O-acyl acid taxol derivatives, succinyltaxol, 2'-γ-aminobutyryltaxol formate, 2'-acetyl taxol, 7-acetyl taxol, 7-glycine carbamate taxol, 2'-OH-7-PEG(5000) carbamate taxol, 2'-benzoyl and 2',7-dibenzoyl taxol derivatives, other prodrugs (2'-acetyltaxol; 2',7-diacetyltaxol; 2'succinyltaxol; 2'-(beta-alanyl)-taxol); 2'gamma-aminobutyryltaxol formate; ethylene glycol derivatives of 2'-succinyltaxol; 2'-glutaryltaxol; 2'-(N,N-dimethylglycyl) taxol; 2'-(2-(N,N-dimethylamino)propionyl)taxol; 2'orthocarboxybenzoyl taxol; 2'aliphatic carboxylic acid derivatives of taxol, Prodrugs {2'(N,N-diethylaminopropionyl)taxol, 2'(N,N-dimethylglycyl)taxol, 7(N,N-dimethylglycyl)taxol, 2',7-di-(N,N-dimethylglycyl)taxol, 7(N,N-diethylaminopropionyl)taxol, 2',7-di(N,N-diethylaminopropionyl)taxol, 2'-(L-glycyl)taxol, 7-(L-glycyl)taxol, 2',7-di(L-glycyl)taxol, 2'-(L-alanyl)taxol, 7-(L-alanyl)taxol, 2',7-di(L-alanyl)taxol, 2'-(L-leucyl)taxol, 7-(L-leucyl)taxol, 2',7-di(L-leucyl)taxol, 2'-(L-isoleucyl)taxol, 7-(L-isoleucyl)taxol, 2',7-di(L-isoleucyl)taxol, 2'-(L-valyl)taxol, 7-(L-valyl)taxol, 2'7-di(L-valyl)taxol, 2'-(L-phenylalanyl)taxol, 7-(L-phenylalanyl)taxol, 2',7-di(L-phenylalanyl)taxol, 2'-(L-prolyl)taxol, 7-(L-prolyl)taxol, 2',7-di(L-prolyl)taxol, 2'-(L-lysyl)taxol, 7-(L-lysyl)taxol, 2',7-di(L-lysyl)taxol, 2'-(L-glutamyl)taxol, 7-(L-glutamyl)taxol, 2',7-di(L-glutamyl)taxol, 2'-(L-arginyl)taxol, 7-(L-arginyl)taxol, 2',7-di(L-arginyl)taxol}, Taxol analogs with modified phenylisoserine side chains, taxotere, (N-debenzoyl-N-tert-(butoxycaronyl)-10-deacetyltaxol, and taxanes (*e.g.*, baccatin III, cephalomannine, 10-deacetylbaccatin III, brevifoliol,

yunantaxusin and taxusin); and other taxane analogues and derivatives, including 14-beta-hydroxy-10 deacetybaccatin III, debenzoyl-2-acyl paclitaxel derivatives, benzoate paclitaxel derivatives, phosphonooxy and carbonate paclitaxel derivatives, sulfonated 2'-acryloyltaxol; sulfonated 2'-O-acyl acid paclitaxel derivatives, 18-site-substituted paclitaxel derivatives, chlorinated paclitaxel analogues, C4 methoxy ether paclitaxel derivatives, sulfenamide taxane derivatives, brominated paclitaxel analogues, Girard taxane derivatives, nitrophenyl paclitaxel, 10-deacetylated substituted paclitaxel derivatives, 14- beta -hydroxy-10 deacetylbaccatin III taxane derivatives, C7 taxane derivatives, C10 taxane derivatives, 2-debenzoyl-2-acyl taxane derivatives, 2-debenzoyl and -2-acyl paclitaxel derivatives, taxane and baccatin III analogs bearing new C2 and C4 functional groups, n-acyl paclitaxel analogues, 10-deacetylbaccatin III and 7-protected-10-deacetylbaccatin III derivatives from 10-deacetyl taxol A, 10-deacetyl taxol B, and 10-deacetyl taxol, benzoate derivatives of taxol, 2-aroyl-4-acyl paclitaxel analogues, orthro-ester paclitaxel analogues, 2-aroyl-4-acyl paclitaxel analogues and 1-deoxy paclitaxel and

1-deoxy paclitaxel analogues.


In one aspect, the Cell Cycle Inhibitor is a taxane having the formula (C1):



(C1),


where the gray-highlighted portions may be substituted and the non-highlighted portion is the taxane core. A side-chain (labeled "A" in the diagram) is desirably present in order for the compound to have good activity as a Cell Cycle Inhibitor. Examples of compounds having this structure include paclitaxel (Merck Index entry 7117), docetaxol (Taxotere, Merck Index entry 3458), and 3'-desphenyl-3'-(4-ntirophenyl)-N-debenzoyl-N-(t-butoxycarbonyl)-10-deacetyltaxol.

In one aspect, suitable taxanes such as paclitaxel and its analogs and derivatives are disclosed in Patent No. 5,440,056 as having the structure (C2):



(C2)


wherein X may be oxygen (paclitaxel), hydrogen (9-deoxy derivatives), thioacyl, or dihydroxyl precursors; R_1 is selected from paclitaxel or taxotere side chains or alkanoyl of the formula (C3)



(C3)

wherein R_7 is selected from hydrogen, alkyl, phenyl, alkoxy, amino, phenoxy (substituted or unsubstituted); R_8 is selected from hydorgen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, phenyl (substituted or unsubstituted), alpha or beta-naphthyl; and R_9 is selected from hydrogen, alkanoyl, substituted alkanoyl, and aminoalkanoyl; where substitutions refer to hydroxyl, sulfhydryl, allalkoxyl, carboxyl, halogen, thioalkoxyl, N,N-dimethylamino, alkylamino, dialkylamino, nitro, and $-OSO_3H$, and/or may refer to groups containing such substitutions; R_2 is selected from hydrogen or oxygen-containing groups, such as hydrogen, hydroxyl, alkoyl, alkanoyloxy, aminoalkanoyloxy, and peptidyalkanoyloxy; R_3 is selected from hydrogen or oxygen-containing groups, such as hydrogen, hydroxyl, alkoyl, alkanoyloxy, aminoalkanoyloxy, and peptidyalkanoyloxy, and may further be a silyl containing group or a sulphur containing group; R_4 is selected from acyl, alkyl, alkanoyl, aminoalkanoyl, peptidylalkanoyl and aroyl; R_5 is selected from acyl, alkyl, alkanoyl, aminoalkanoyl, peptidylalkanoyl and aroyl; R_6 is selected from hydrogen or oxygen-containing groups, such as hydrogen, hydroxyl alkoyl, alkanoyloxy, aminoalkanoyloxy, and peptidyalkanoyloxy.

In one aspect, the paclitaxel analogs and derivatives useful as Cell Cycle Inhibitors in the present invention are disclosed in PCT International Patent Application No. WO 93/10076. As disclosed in this publication, the analog or derivative should have a side chain attached to the taxane nucleus at C_{13}, as shown in the structure below (formula C4), in order to confer antitumor activity to the taxane.




(C4)

WO 93/10076 discloses that the taxane nucleus may be substituted at any position with the exception of the existing methyl groups. The substitutions may include, for example, hydrogen, alkanoyloxy, alkenoyloxy, aryloyloxy. In addition, oxo groups may be attached to carbons labeled 2, 4, 9, 10. As well, an oxetane ring may be attached at carbons 4 and 5. As well, an oxirane ring may be attached to the carbon labeled 4.

In one aspect, the taxane-based Cell Cycle Inhibitor useful in the present invention is disclosed in U.S. Patent 5,440,056, which discloses 9-deoxo taxanes. These are compounds lacking an oxo group at the carbon labeled 9 in the taxane structure shown above (formula C4). The taxane ring may be substituted at the carbons labeled 1, 7 and 10 (independently) with H, OH, O-R, or O-CO-R where R is an alkyl or an aminoalkyl. As well, it may be substituted at carbons labeled 2 and 4 (independently) with aryol, alkanoyl, aminoalkanoyl or alkyl groups. The side chain of formula (C3) may be substituted at R_7 and R_8 (independently) with phenyl rings, substituted phenyl rings, linear alkanes/alkenes, and groups containing H, O or N. R_9 may be substituted with H, or a substituted or unsubstituted alkanoyl group.


Taxanes in general, and paclitaxel is particular, is considered to function as a Cell Cycle Inhibitor by acting as a anti-microtuble agent, and more specifically as a stabilizer.

In another aspect, the Cell Cycle Inhibitor is a Vinca Alkaloid. Vinca alkaloids have the following general structure. They are indole-dihydroindole dimers.



As disclosed in U.S. Patent Nos. 4,841,045 and 5,030,620, R_1 can be a formyl or methyl group or alternately H. R_1 could also be an alkyl group or an aldehyde-substituted alkyl (*e.g.*, CH_2CHO). R_2 is typically a CH_3 or NH_2 group. However it can be alternately substituted with a lower alkyl ester or the ester linking to the dihydroindole core may be substituted with C(O)-R where R is NH_2, an amino acid ester or a peptide ester. R_3 is typically $C(O)CH_3$, CH_3 or H. Alternately, a protein fragment may be linked by a bifunctional group such as maleoyl amino acid. R_3 could also be substituted to form an alkyl ester which may be further substituted. R_4 may be $-CH_2-$ or a single bond. R_5 and R_6 may be H, OH or a lower alkyl, typically $-CH_2CH_3$. Alternatively R_6 and R_7 may together form an oxetane ring. R_7 may alternately be H. Further substitutions include molecules wherein methyl groups are substituted with other alkyl groups, and whereby unsaturated rings may be derivatized by the addition of a side group such as an alkane, alkene, alkyne, halogen, ester, amide or amino group.


Exemplary Vinca Alkaloids are vinblastine, vincristine, vincristine sulfate, vindesine, and vinorelbine, having the structures:



	R_1	R_2	R_3	R_4	R_5
Vinblastine:	CH_3	CH_3	$C(O)CH_3$	OH	CH_2
Vincristine:	CH_2O	CH_3	$C(O)CH_3$	OH	CH_2
Vindesine:	CH_3	NH_2	H	OH	CH_2
Vinorelbine:	CH_3	CH_3	CH_3	H	single bond


Analogs typically require the side group (shaded area) in order to have activity. These compounds are believed to act as Cell Cycle Inhibitors by functioning as anti-microtubule agents, and more specifically to inhibit polymerization.

In another aspect, the Cell Cycle Inhibitor is Camptothecin, or an analog or derivative thereof. Camptothecins have the following general structure.



In this structure, X is typically O, but can be other groups, *e.g.*, NH in the case of 21-lactam derivatives. R_1 is typically H or OH, but may be other groups, *e.g.*, a terminally hydroxylated C_{1-3} alkane. R_2 is typically H or an amino containing group such as $(CH_3)_2NHCH_2$, but may be other groups *e.g.*, NO_2, NH_2, halogen (as disclosed in, *e.g.*, U.S. Patent 5,552,156) or a short alkane containing these groups. R_3 is typically H or a short alkyl such as C_2H_5. R_4 is typically H but may be other groups, *e.g.*, a methylenedioxy group with R_1.

Exemplary camptothecin compounds include topotecan, irinotecan (CPT-11), 9-aminocamptothecin, 21-lactam-20(S)-camptothecin, 10,11-methylenedioxycamptothecin, SN-38, 9-nitrocamptothecin, 10-hydroxycamptothecin. Exemplary compounds have the structures:




	R_1	R_2	R_3
Camptothecin:	H	H	H
Topotecan:	OH	$(CH_3)_2NHCH_2$	H
SN-38:	OH	H	C_2H_5

X: O for most analogs, NH for 21-lactam analogs

Camptothecins have the five rings shown here. The ring labeled E must be intact (the lactone rather than carboxylate form) for maximum activity and minimum toxicity. These compounds are useful to as Cell Cycle Inhibitors, where they function as Topoisomerase I Inhibitors and/or DNA cleavage agents.


In another aspect, the Cell Cycle Inhibitor is a Podophyllotoxin, or a derivative or an analog thereof. Exemplary compounds of this type are Etoposide or Teniposide, which have the following structures:



	R
Etoposide	CH_3
Teniposide	S


These compounds are believed to function as Cell Cycle Inhibitors by being Topoisomerase II Inhibitors and/or by DNA cleaving agents.

In another aspect, the Cell Cycle Inhibitor is an Anthracycline. Anthracyclines have the following general structure, where the R groups may be a variety of organic groups:




According to U.S. Patent 5,594,158, suitable R groups are: R_1 is CH_3 or CH_2OH; R_2 is daunosamine or H; R_3 and R_4 are independently one of OH, NO_2, NH_2, F, Cl, Br, I, CN, H or groups derived from these; R_{5-7} are all H or R_5 and R_6 are H and R_7 and R_8 are alkyl or halogen, or vice versa: R_7 and R_8 are H and R_5 and R_6 are alkyl or halogen.

According to U.S. Patent 5,843,903, R_2 may be a conjugated peptide. According to U.S. Patent Nos. 4,215,062 and 4,296,105, R_5 may be OH or an ether linked alkyl group. R_1 may also be linked to the anthracycline ring by a group other than C(O), such as an alkyl or branched alkyl group having the C(O) linking moiety at its end, such as $-CH_2CH(CH_2-X)C(O)-R_1$, wherein X is H or an alkyl group (see, *e.g.*, U.S. Patent 4,215,062). R_2 may alternately be a group linked by the functional group =N-NHC(O)-Y, where Y is a group such as a phenyl or substituted phenyl ring. Alternately R_3 may have the following structure:





in which R_9 is OH either in or out of the plane of the ring, or is a second sugar moiety such as R_3. R_{10} may be H or form a secondary amine with a group such as an aromatic group, saturated or partially saturated 5 or 6 membered heterocyclic having at least one ring nitrogen (*see* U.S. Patent 5,843,903). Alternately, R_{10} may be derived from an amino acid, having the structure $-C(O)CH(NHR_{11})(R_{12})$, in which R_{11} is H, or forms a C_{3-4} membered alkylene with R_{12}. R_{12} may be H, alkyl, aminoalkyl, amino, hydroxy, mercapto, phenyl, benzyl or methylthio (*see* U.S. Patent 4,296,105).

Exemplary Anthracycline are Doxorubicin, Daunorubicin, Idarubicin, Epirubicin, Pirarubicin, Zorubicin, and Carubicin. Suitable compounds have the structures:




	R_1	R_2	R_3
Doxorubicin:	OCH_3	CH_2OH	OH out of ring plane
Epirubicin: (4' epimer of doxorubicin)	OCH_3	CH_2OH	OH in ring plane
Daunorubicin:	OCH_3	CH_3	OH out of ring plane
Idarubicin:	H	CH_3	OH out of ring plane
Pirarubicin	OCH_3	OH	A
Zorubicin	OCH_3	$=N\text{-}NHC(O)C_6H_5$	B
Carubicin	OH	CH_3	B


A: 

B: 


Other suitable Anthracyclines are Anthramycin, Mitoxantrone, Menogaril, Nogalamycin, Aclacinomycin A, Olivomycin A, Chromomycin A_3, and Plicamycin having the structures:




Anthramycin




Mitoxantrone




	R_1	R_2	R_3
Menogaril	H	OCH_3	H
Nogalamycin	O-sugar	H	$COOCH_3$

sugar: 




	R_1	R_2	R_3	R_4
Olivomycin A	$COCH(CH_3)_2$	CH_3	$COCH_3$	H
Chromomycin A_3	$COCH_3$	CH_3	$COCH_3$	CH_3
Plicamycin	H	H	H	CH_3



Aclacinomycin A


These compounds are believed to function as Cell Cycle Inhibitors by being Topoisomerase Inhibitors and/or by DNA cleaving agents.

In another aspect, the Cell Cycle Inhibitor is a Platinum compound. In general, suitable platinum complexes may be of Pt(II) or Pt(IV) and have this basic structure:





wherein X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen; R_1 and R_2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups. For Pt(II) complexes Z_1 and Z_2 are non-existent. For Pt(IV) Z_1 and Z_2 may be anionic groups such as halogen, hydroxy, carboxylate, ester, sulfate or phosphate. *See, e.g.*, U.S. Patent Nos. 4,588,831 and 4,250,189.

Suitable platinum complexes may contain multiple Pt atoms. *See, e.g.*, U.S. Patent Nos. 5,409,915 and 5,380,897. For example bisplatinum and triplatinum complexes of the type:




Exemplary Platinum compound are Cisplatin, Carboplatin, Oxaliplatin, and Miboplatin having the structures:






These compounds are believed to function as Cell Cycle Inhibitors by binding to DNA, *i.e.*, acting as alkylating agents of DNA.

In another aspect, the Cell Cycle Inhibitor is a Nitrosourea. Nitrosourease have the following general structure (C5), where typical R groups are shown below.




(C5)


R Group:




Carmustine




Ranimustine




Lomustine







Fotemustine



Nimustine



Chlorozotocin




Streptozocin


Other suitable R groups include cyclic alkanes, alkanes, halogen substituted groups, sugars, aryl and heteroaryl groups, phosphonyl and sulfonyl groups. As disclosed in U.S. Patent No. 4,367,239, R may suitably be CH_2-C(X)(Y)(Z), wherein X and Y may be the same or different members of the following groups: phenyl, cyclyhexyl, or a phenyl or cyclohexyl group substituted with groups such as halogen, lower alkyl (C_{1-4}), trifluore methyl, cyano, phenyl, cyclohexyl, lower alkyloxy (C_{1-4}). Z has the following structure: -alkylene-N-R_1R_2, where R_1 and R_2 may be the same or different members of the following group: lower alkyl (C_{1-4}) and benzyl, or together R_1 and R_2 may form a saturated 5 or 6 membered heterocyclic such as pyrrolidine, piperidine, morfoline, thiomorfoline, N-lower alkyl piperazine, where the heterocyclic may be optionally substituted with lower alkyl groups.

As disclosed in U.S. Patent No. 6,096,923, R and R' of formula (C5) may be the same or different, where each may be a substituted or unsubstituted hydrocarbon having 1-10 carbons. Substitutions may include hydrocarbyl, halo, ester, amide, carboxylic acid, ether, thioether and alcohol groups. As disclosed in U.S. Patent No. 4,472,379, R of formula (C5) may be an amide bond and a pyranose structure (*e.g.*, Methyl 2'-[N-[N-(2-chloroethyl)-N-nitroso-carbamoyl]-glycyl]amino-2'-deoxy-α-D-glucopyranoside). As disclosed in U.S. Patent No. 4,150,146, R of formula (C5) may

be an alkyl group of 2 to 6 carbons and may be substituted with an ester, sulfonyl, or hydroxyl group. It may also be substituted with a carboxylica acid or $CONH_2$ group.


Exemplary Nitrosourea are BCNU (Carmustine), Methyl-CCNU (Semustine), CCNU (Lomustine), Ranimustine, Nimustine, Chlorozotocin, Fotemustine, Streptozocin, and Streptozocin, having the structures:





These nitrosourea compounds are believed to function as Cell Cycle Inhibitor by binding to DNA, that is, by functioning as DNA alkylating agents.


In another aspect, the Cell Cycle Inhibitor is a Nitroimidazole, where exemplary Nitroimidazoles are Metronidazole, Benznidazole, Etanidazole, and Misonidazole, having the structures:




	R_1	R_2	R_3
Metronidazole	OH	CH_3	NO_2
Benznidazole	$C(O)NHCH_2$-benzyl	NO_2	H
Etanidazole	$CONHCH_2CH_2OH$	NO_2	H

Suitable nitroimidazole compounds are disclosed in, *e.g.*, U.S. Patent Nos. 4,371,540 and 4,462,992.

In another aspect, the Cell Cycle Inhibitor is a Folic acid antagonist, such as Methotrexate or derivatives or analogs thereof, including Edatrexate, Trimetrexate, Raltitrexed, Piritrexim, Denopterin, Tomudex, and Pteropterin. Methotrexate analogs have the following general structure:




The identity of the R group may be selected from organic groups, particularly those groups set forth in U.S. Patent Nos. 5,166,149 and 5,382,582. For example, R_1 may be N, R_2 may be N or $C(CH_3)$, R_3 and R_3' may H or alkyl, *e.g.*, CH_3, R_4 may be a single bond or NR, where R is H or alkyl group. $R_{5,6,8}$ may be H, OCH_3, or alternately they can be halogens or hydro groups. R_7 is a side chain of the general structure:




wherein n = 1 for methotrexate, n = 3 for pteropterin. The carboxyl groups in the side chain may be esterified or form a salt such as a Zn^{2+} salt. R_9 and R_{10} can be NH_2 or may be alkyl substituted.


Exemplary folic acid antagonist compounds have the structures:



	R_0	R_1	R_2	R_3	R_4	R_5	R_6	R_7	R_8
Methotrexate	NH_2	N	N	H	$N(CH_3)$	H	H	A (n=1)	H
Edatrexate	NH_2	N	N	H	$N(CH_2CH_3)$	H	H	A (n=1)	H
Trimetrexate	NH_2	N	$C(CH_3)$	H	NH	H	OCH_3	OCH_3	OCH_3
Pteropterin	NH_2	N	N	H	$N(CH_3)$	H	H	A (n=3)	H
Denopterin	OH	N	N	CH_3	$N(CH_3)$	H	H	A (n=1)	H
Piritrexim	NH_2	N	$C(CH_3)$ H	single bond	OCH_3	H	H	OCH_3	H

A:







Tomudex

These compounds are believed to function as Cell Cycle Inhibitors by serving as antimetabolites of folic acid.

In another aspect, the Cell Cycle Inhibitor is a Cytidine Analog, such as Cytarabine or derivatives or analogs thereof, including Enocitabine, FMdC ((E(-2'-deoxy-2'-(fluoromethylene)cytidine), Gemcitabine, 5-Azacitidine, Ancitabine, and 6-Azauridine. Exemplary compounds have the structures:




	R_1	R_2	R_3	R_4
Cytarabine	H	OH	H	CH
Enocitabine	$C(O)(CH_2)_{20}CH_3$	OH	H	CH
Gemcitabine	H	F	F	CH
Azacitidine	H	H	OH	N
FMdC	H	CH_2F	H	CH




Ancitabine 6-Azauridine

These compounds are believed to function as Cell Cycle Inhibitors as acting as antimetabolites of pyrimidine.

In another aspect, the Cell Cycle Inhibitor is a Pyrimidine analog. In one aspect, the Pyrimidine analogs have the general structure:




wherein positions 2', 3' and 5' on the sugar ring (R_2, R_3 and R_4, respectively) can be H, hydroxyl, phosphoryl (*see, e.g.*, U.S. Patent 4,086,417) or ester (*see, e.g.*, U.S. Patent 3,894,000). Esters can be of alkyl, cycloalkyl, aryl or heterocyclo/aryl types. The 2' carbon can be hydroxylated at either R_2 or R_2', the other group is H. Alternately, the 2' carbon can be substituted with halogens *e.g.*, fluoro or difluoro cytidines such as Gemcytabine. Alternately, the sugar can be substituted for another heterocyclic group such as a furyl group or for an alkane, an alkyl ether or an amide linked alkane such as $C(O)NH(CH_2)_5CH_3$. The 2° amine can be substituted with an aliphatic acyl (R_1) linked with an amide (*see, e.g.*, U.S. Patent 3,991,045) or urethane (*see, e.g.*, U.S. Patent 3,894,000) bond. It can also be further substituted to form a quaternary ammonium salt. R_5 in the pyrimidine ring may be N or CR, where R is H, halogen containing groups, or alkyl (*see, e.g.*, U.S. Patent No. 4,086,417). R_6 and R_7 can together can form an oxo group or R_6 = -NH-R_1 and R_7 = H. R_8 is H or R_7 and R_8 together can form a double bond or R_8 can be X, where X is:





Specific pyrimidine analogs are disclosed in U.S. Patent No. 3,894,000 (*see, e.g.*, 2'-O-palmityl-ara-cytidine, 3'-O-benzoyl-ara-cytidine, and more than 10 other examples); U.S. Patent No. 3,991,045 (*see, e.g.*, N4-acyl-1-β-D-arabinofuranosylcytosine, and numerous acyl groups derivatives as listed therein, such as palmitoyl.


In another aspect, the Cell Cycle Inhibitor is a Fluoro-pyrimidine Analog, such as 5-Fluorouracil, or an analog or derivative thereof, including Carmofur, Doxifluridine, Emitefur, Tegafur, and Floxuridine. Exemplary compounds have the structures:




	R_1	R_2
5-Fluorouracil	H	H
Carmofur	$C(O)NH(CH_2)_5CH_3$	H
Doxifluridine	A_1	H
Floxuridine	A_2	H
Emitefur	$CH_2OCH_2CH_3$	B
Tegafur	C	H








Other suitable Fluoropyrimidine Analogs include 5-FudR (5-fluoro-deoxyuridine), or an analog or derivative thereof, including 5-iododeoxyuridine (5-IudR), 5-bromodeoxyuridine (5-BudR), Fluorouridine triphosphate (5-FUTP), and Fluorodeoxyuridine monophosphate (5-dFUMP). Exemplary compounds have the structures:



5-Fluoro-2'-deoxyuridine: R = F
5-Bromo-2'-deoxyuridine: R = Br
5-Iodoo-2'-deoxyuridine: R = I

These compounds are believed to function as Cell Cycle Inhibitors by serving as antimetabolites of pyrimidine.


In another aspect, the Cell Cycle Inhibitor is a Purine Analog. Purine analogs have the following general structure:



wherein X is typically carbon; R_1 is H, halogen, amine or a substituted phenyl; R_2 is H, a primary, secondary or tertiary amine, a sulfur containing group, typically –SH, an alkane, a cyclic alkane, a heterocyclic or a sugar; R_3 is H, a sugar (typically a furanose or pyranose structure), a substituted sugar or a cyclic or heterocyclic alkane or aryl group. *See, e.g.*, U.S. Patent No. 5,602,140 for compounds of this type.


In the case of pentostatin, X-R2 is $-CH_2CH(OH)-$. In this case a second carbon atom is inserted in the ring between X and the adjacent nitrogen atom. The X-N double bond becomes a single bond.

U.S. Patent No. 5,446,139 describes suitable purine analogs of the type shown in the following formula:



wherein N signifies nitrogen and V, W, X, Z can be either carbon or nitrogen with the following provisos. Ring A may have 0 to 3 nitrogen atoms in its structure. If two nitrogens are present in ring A, one must be in the W position. If only one is present, it must not be in the Q position. V and Q must not be simultaneously nitrogen. Z and Q must not be simultaneously nitrogen. If Z is nitrogen, R_3 is not present. Furthermore, R_{1-3} are independently one of H, halogen, C_{1-7} alkyl, C_{1-7} alkenyl, hydroxyl, mercapto, C_{1-7} alkylthio, C_{1-7} alkoxy, C_{2-7} alkenyloxy, aryl oxy, nitro, primary, secondary or tertiary amine containing group. R_{5-8} are H or up to two of the positions may contain independently one of OH, halogen, cyano, azido, substituted amino, R_5 and R_7 can together form a double bond. Y is H, a C_{1-7} alkylcarbonyl, or a mono- di or tri phosphate.


Exemplary suitable purine analogs include 6-Mercaptopurine, Thiguanosine, Thiamiprine, Cladribine, Fludaribine, Tubercidin, Puromycin, Pentoxyfilline; where these compounds may optionally be phosphorylated. Exemplary compounds have the structures:



These compounds are believed to function as Cell Cycle Inhibitors by serving as antimetabolites of purine.


In another aspect, the Cell Cycle Inhibitor is a Nitrogen Mustard. Many suitable Nitrogen Mustards are known and are suitably used as a Cell Cycle Inhibitor in the present invention. Suitable nitrogen mustards are also known as cyclophosphamides.

A preferred nitrogen mustard has the general structure:




(i)


Where A is:




or $-CH_3$ or other alkane, or chloronated alkane, typically $CH_2CH(CH_3)Cl$, or a polycyclic group such as B, or a substituted phenyl such as C or a heterocyclic group such as D.



(ii)




(iii)




(iv)

Suitable nitrogen mustards are disclosed in U.S. Patent No. 3,808,297, wherein A is:




$R_{1\text{-}2}$ are H or CH_2CH_2Cl; R_3 is H or oxygen-containing groups such as hydroperoxy; and R_4 can be alkyl, aryl, heterocyclic.

The cyclic moiety need not be intact. *See, e.g.*, U.S. Patent Nos. 5,472,956, 4,908,356, 4,841,085 that describe the following type of structure:




wherein R_1 is H or CH_2CH_2Cl, and R_{2-6} are various substituent groups.

Exemplary nitrogen mustards include methylchloroethamine, and analogs or derivatives thereof, including methylchloroethamine oxide hydrohchloride, Novembichin, and Mannomustine (a halogenated sugar). Exemplary compounds have the structures:




	R
Mechlorethanime	CH_3
Novembichin	$CH_2CH(CH_3)Cl$




Mechlorethanime Oxide HCl

The Nitrogen Mustard may be Cyclophosphamide, Ifosfamide, Perfosfamide, or Torofosfamide, where these compounds have the structures:




	R_1	R_2	R_3
Cyclophosphamide	H	CH_2CH_2Cl	H
Ifosfamide	CH_2CH_2Cl	H	H
Perfosfamide	CH_2CH_2Cl	H	OOH
Torofosfamide	CH_2CH_2Cl	CH_2CH_2Cl	H

The Nitrogen Mustard may be Estramustine, or an analog or derivative thereof, including Phenesterine, Prednimustine, and Estramustine PO_4. Thus, suitable nitrogen mustard type Cell Cycle Inhibitors of the present invention have the structures:




	R
Estramustine	OH
Phenesterine	$C(CH_3)(CH_2)_3CH(CH_3)_2$




Prednimustine

The Nitrogen Mustard may be Chlorambucil, or an analog or derivative thereof, including Melphalan and Chlormaphazine. Thus, suitable nitrogen mustard type Cell Cycle Inhibitors of the present invention have the structures:




	R_1	R_2	R_3
Chlorambucil	CH_2COOH	H	H
Melphalan	COOH	NH_2	H
Chlornaphazine	H	together forms a benzene ring	

The Nitrogen Mustard may be Uracil Mustard, which has the structure:




The Nitrogen Mustards are believed to function as Cell Cycle Inhibitors by serving as alkylating agents for DNA. Nitrogen Mustards have been shown useful in the treatment of cell proliferative disorders including, for example, small cell lung, breast, cervical, head and neck, prostate, retinoblastoma, and soft tissue sarcoma.

The Cell Cycle Inhibitor of the present invention may be a Hydroxyurea. Hydroxyureas have the following general structure:



Suitable Hydroxyureas are disclosed in, for example, U.S. Patent No. 6,080,874, wherein R_1 is:




;

and R_2 is an alkyl group having 1-4 carbons and R_3 is one of H, acyl, methyl, ethyl, and mixtures thereof, such as a methylether.

Other suitable Hydroxyureas are disclosed in, *e.g.*, U.S. Patent No. 5,665,768, wherein R_1 is a cycloalkenyl group, for example N-[3-[5-(4-fluorophenylthio)-furyl]-2-cyclopenten-1-yl]N-hydroxyurea; R_2 is H or an alkyl group having 1 to 4 carbons and R_3 is H; X is H or a cation.


Other suitable Hydroxyureas are disclosed in, *e.g.*, U.S. Patent No. 4,299,778, wherein R_1 is a phenyl group substituted with on or more fluorine atoms; R_2 is a cyclopropyl group; and R_3 and X is H.

Other suitable Hydroxyureas are disclosed in, *e.g.*, U.S. Patent No. 5,066,658, wherein R_2 and R_3 together with the adjacent nitrogen form:



wherein m is 1 or 2, n is 0-2 and Y is an alkyl group.


In one aspect, the hydroxy urea has the structure:



Hydroxyurea

Hydroxyureas are believed to function as Cell Cycle Inhibitors by serving to inhibit DNA synthesis.


In another aspect, the Cell Cycle Inhibitor is a Belomycin, such as Bleomycin A_2, which have the structures:



Bleomycin A_2: R = $(CH_3)_2S^+(CH_2)_3NH$-

Belomycins are believed to function as Cell Cycle Inhibitors by cleaving DNA.


In another aspect, the Cell Cycle Inhibitor is a Mytomycin, such as Mitomycin C, or an analog or derivative thereof, such as Porphyromycin. Suitable compounds have the structures:



	R
Mitomycin C	H
Porphyromycin (N-methyl Mitomycin C)	CH_3

These compounds are believed to function as Cell Cycle Inhibitors by serving as DNA alkylating agents.

In another aspect, the Cell Cycle Inhibitor is an Alkyl sulfonate, such as Busulfan, or an analog or derivative thereof, such as Treosulfan, Improsulfan, Piposulfan, and Pipobroman. Exemplary compounds have the structures:





R

Busulfan — single bond

Improsulfan — $-CH_2-NH-CH_2-$

Piposulfan






Pipobroman


These compounds are believed to function as Cell Cycle Inhibitors by serving as DNA alkylating agents.

In another aspect, the Cell Cycle Inhibitor is a Benzamide. In yet another aspect, the Cell Cycle Inhibitor is a Nicotinamide. These compounds have the basic structure:



wherein X is either O or S; A is commonly NH_2 or it can be OH or an alkoxy group; B is N or C-R_4, where R_4 is H or an ether-linked hydroxylated alkane such as OCH_2CH_2OH, the alkane may be linear or branched and may contain one or more hydroxyl groups. Alternately, B may be N-R_5 in which case the double bond in the ring involving B is a single bond. R_5 may be H, and alkyl or an aryl group (see, *e.g.*, U.S. Patent No. 4,258,052); R_2 is H, OR_6, SR_6 or NHR_6, where R_6 is an alkyl group; and R_3 is H, a lower alkyl, an ether linked lower alkyl such as –O-Me or –O-Ethyl (*see, e.g.*, U.S. Patent No. 5,215,738).


Suitable Benzamide compounds have the structures:



Benzamides
X = O or S
Y = H, OR, CH_3, acetoxy
Z = H, OR, SR, NHR
R = alkyl group


where additional compounds are disclosed in U.S. Patent No. 5,215,738, (listing some 32 compounds).

Suitable Nicotinamide compounds have the structures:



Nicotinamides
X = O or S
Z = H, OR, SR, NHR
R = alkyl group


where additional compounds are disclosed in U.S. Patent No. 5,215,738 (listing some 58 compounds, *e.g.*, 5-OH nicotinamide, 5-aminonicotinamide, 5-(2,3-dihydroxypropoxy) nicotinamide), and compounds having the structures:



Nicotinamides
X = O or S (only O is described)
A = OH, NH_2, alkoxy
B = O .
R = alkyl or aryl group


and U.S. Patent No. 4,258,052 (listing some 46 compounds, *e.g.*, 1-methyl-6-keto-1,6-dihydronicotinic acid).

In one aspect, the Cell Cycle Inhibitor is a Tetrazine Compound, such as Temozolomide, or an analog or derivative thereof, including Dacarbazine. Suitable compounds have the structures:




Temozolomide Dacarbazine

Another suitable Tetrazine Compound is Procarbazine, including HCl and HBr salts, having the structure:




Procarbazine

In another aspect, the Cell Cycle Inhibitor is Actinomycin D, or other members of this family, including Dactinomycin, Actinomycin C_1, Actinomycin C_2, Actinomycin C_3, and Actinomycin F_1. Suitable compounds have the structures:




	R_1	R_2	R_3
Actinomycin D (C_1)	D-Val	D-Val	single bond
Actinomycin C_2	D-Val	D-Alloisoleucine	O
Actinomycin C_3	D-Alloisoleucine	D-Alloisoleucine	O

In another aspect, the Cell Cycle Inhibitor is an Aziridine compound, such as Benzodepa, or an analog or derivative thereof, including Meturedepa, Uredepa, and Carboquone. Suitable compounds have the structures:




	R_1	R_2
Benzodepa	phenyl	H
Meturedepa	CH_3	CH_3
Uredepa	CH_3	H




Carboquone


In another aspect, the Cell Cycle Inhibitor is Halogenated Sugar, such as Mitolactol, or an analog or derivative thereof, including Mitobronitol and Mannomustine. Suitable compounds have the structures:



Mitolactol




Mitobronitol



Mannomustine

In another aspect, the Cell Cycle Inhibitor is a Diazo compound, such as Azaserine, or an analog or derivative thereof, including 6-diazo-5-oxo-L-norleucine and 5-diazouracil (also a pyrimidine analog). Suitable compounds have the structures:



	R_1	R_2
Azaserine	O	single bond
6-diazo-5-oxo-L-norleucine	single bond	CH_2

Other compounds that may serve as Cell Cycle Inhibitors according to the present invention are Pazelliptine; Wortmannin; Metoclopramide; RSU; Buthionine sulfoxime; Tumeric; Curcumin; AG337, a thymidylate synthase inhibitor; Levamisole; Lentinan, a polysaccharide; Razoxane, an EDTA analog; Indomethacin;

Chlorpromazine; α and β interferon; MnBOPP; Gadolinium texaphyrin; 4-amino-1,8-naphthalimide; Staurosporine derivative of CGP; and SR-2508.

Thus, in one aspect, the Cell Cycle Inhibitor is a DNA alkylating agent. In another aspect, the Cell Cycle Inhibitor is an anti-microtubule agent. In another aspect, the Cell Cycle Inhibitor is a Topoisomerase inhibitor. In another aspect, the Cell Cycle Inhibitor is a DNA cleaving agent. In another aspect, the Cell Cycle Inhibitor is an antimetabolite. In another aspect, the Cell Cycle Inhibitor functions by inhibiting adenosine deaminase (*e.g.*, as a purine analog). In another aspect, the Cell Cycle Inhibitor functions by inhibiting purine ring synthesis and/or as a nucleotide interconversion inhibitor (*e.g.*, as a purine analog such as mercaptopurine). In another aspect, the Cell Cycle Inhibitor functions by inhibiting dihydrofolate reduction and/or as a thymidine monophosphate block (*e.g.*, methotrexate). In another aspect, the Cell Cycle Inhibitor functions by causing DNA damage (*e.g.*, Bleomycin). In another aspect, the Cell Cycle Inhibitor functions as a DNA intercalation agent and/or RNA synthesis inhibition (*e.g.*, Doxorubicin). In another aspect, the Cell Cycle Inhibitor functions by inhibiting pyrimidine synthesis (*e.g.*, N-phosphonoacetyl-L-Aspartate). In another aspect, the Cell Cycle Inhibitor functions by inhibiting ribonucleotides (*e.g.*, hydroxyurea). In another aspect, the Cell Cycle Inhibitor functions by inhibiting thymidine monophosphate (*e.g.*, 5-fluorouracil). In another aspect, the Cell Cycle Inhibitor functions by inhibiting DNA synthesis (*e.g.*, Cytarabine). In another aspect, the Cell Cycle Inhibitor functions by causing DNA adduct formation (*e.g.*, platinum compounds). In another aspect, the Cell Cycle Inhibitor functions by inhibiting protein synthesis (*e.g.*, L-Asparginase). In another aspect, the Cell Cycle Inhibitor functions by inhibiting microtubule function (*e.g.*, taxanes). In another aspect, the Cell Cycle Inhibitors acts at one or more of the steps in the biological pathway shown in Figure 1.

Additional Cell Cycle Inhibitors useful in the present invention, as well as a discussion of their mechanisms of action, may be found in Hardman J.G., Limbird L.E. Molinoff R.B., Ruddon R W., Gilman A.G. editors, Chemotherapy of Neoplastic Diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics Ninth Edition, McGraw-Hill Health Professions Division, New York, 1996, pages 1225-1287. *See also* U.S. Patent Nos. 3,387,001; 3,808,297; 3,894,000; 3,991,045; 4,012,390; 4,057,548; 4,086,417; 4,144,237; 4,150,146; 4,210,584; 4,215,062; 4,250,189; 4,258,052; 4,259,242; 4,296,105; 4,299,778; 4,367,239; 4,374,414; 4,375,432;

4,472,379; 4,588,831; 4,639,456; 4,767,855; 4,828,831; 4,841,045; 4,841,085; 4,908,356; 4,923,876; 5,030,620; 5,034,320; 5,047,528; 5,066,658; 5,166,149; 5,190,929; 5,215,738; 5,292,731; 5,380,897; 5,382,582; 5,409,915; 5,440,056; 5,446,139; 5,472,956; 5,527,905; 5,552,156; 5,594,158; 5,602,140; 5,665,768; 5,843,903; 6,080,874; 6,096,923; and RE030561 (all of which, as noted above, are incorporated by reference in their entirety)

Numerous polypeptides, proteins and peptides, as well as nucleic acids that encode such proteins, can also be used therapeutically as cell cycle inhibitors. This is accomplished by delivery by a suitable vector or gene delivery vehicle which encodes a cell cycle inhibitor (Walther & Stein, Drugs *60*(2):249-71, Aug 2000; Kim *et al.*, Archives of Pharmacal Res. *24*(1):1-15, Feb 2001; and Anwer *et al.*, Critical Reviews in Therapeutic Drug Carrier Systems *17*(4):377-424, 2000. Genes encoding proteins that modulate cell cycle include the INK4 family of genes (US 5,889,169; US 6,033,847), ARF-p19 (US 5,723,313), $p21^{WAF1/CIP1}$ and $p27^{KIP1}$ (WO 9513375; WO 9835022), $p27^{KIP1}$ (WO 9738091), $p57^{KIP2}$ (US 6,025,480), ATM/ATR (WO 99/04266), Gadd 45 (US 5,858,679), Myt1 (US 5,744,349), Wee1 (WO 9949061) smad 3 and smad 4 (US 6,100,032), 14-3-3σ (WO 9931240), GSK3β (Stambolic, V. and Woodgett, J. R., Biochem Journal *303*: 701-704, 1994), HDAC-1 (Furukawa, Y. *et al.*, Cytogenet. Cell Genet. *73*: 130-133, 1996; Taunton, J. *et al.*, Science *272*: 408-411, 1996), PTEN (WO 9902704), p53 (U.S. 5,532,220), $p33^{ING1}$ (US 5.986.078), Retinoblastoma (EPO 390530), and NF-1 (WO 9200387).

A wide variety of gene delivery vehicles may be utilized to deliver and express the proteins described herein, including for example, viral vectors such as retroviral vectors (*e.g.*, U.S. Patent Nos. 5,591,624, 5,716,832, 5,817,491, 5,856,185, 5,888,502, 6,013,517, and 6,133,029; as well as subclasses of retroviral vectors such as lentiviral vectors (*e.g.*, PCT Publication Nos. WO 00/66759, WO 00/00600, WO 99/24465, WO 98/51810, WO 99/51754, WO 99/31251, WO 99/30742, and WO 99/15641)), alphavirus based vector systems (*e.g.*, U.S. Patent Nos. 5,789,245, 5,814,482, 5,843,723, and 6,015,686), adeno-associated virus-based system (*e.g.*, U.S. Patent Nos. 6,221,646, 6,180,613, 6,165,781, 6,156,303, 6,153,436, 6,093,570, 6,040,183, 5,989,540, 5,856,152, and 5,587,308) and adenovirus-based systems (*e.g.*, U.S. Patent Nos. 6,210,939, 6,210,922, 6,203,975, 6,194,191, 6,140,087, 6,113,913, 6,080,569, 6,063,622, 6,040,174, 6,033,908, 6,033,885, 6,020,191, 6,020,172,

5,994,128, and 5,994,106), herpesvirus based or 'amplicon" systems (*e.g.*, U.S. Patent No. 5,928,913, 5,501,979, 5,830,727, 5,661,033, 4,996,152 and 5,965,441) and, "naked DNA" based systems (*e.g.*, U.S. Patent Nos. 5,580,859 and 5,910,488) (all of which are, as noted above, incorporated by reference in their entirety).

Within one aspect of the invention, ribozymes or antisense sequences (as well as gene therapy vehicles which can deliver such sequences) can be utilized as cell cycle inhibitors. One representative example of such inhibitors is disclosed in PCT Publication No. WO 00/32765 (which, as noted above, is incorporated by reference in its entirety).

Antiproliferative agents.

Intimal hyperplasia is due to the migration and proliferation of cells into the intima followed by extracellular matrix secretion. The main cell types responsible for the hyperplastic response in the intima are smooth muscle cells and fibroblasts. Arterioles and capillaries sprout into the intimal plaque to provide nutrients and oxygen, thus allowing the plaque to grow. Intimal plaque growth eventually leads to occlusion of the lumen of the disease blood vessels with accompanying ischemia to the distal tissues. Hence, within one aspect of the invention, antiproliferative agents may be coated on or otherwise released from a patch.

The antiproliferative activity of the agents can be assayed by quantifying cell migration and proliferation in vitro. Antiproliferative activity can also be determined in vivo by morphometric analysis after vascular injury in various animal models (Signore et al., 2001 J. Vasc. Interv. Radiol. 12: 79-88; Axel et al., 1997 Circulation 96: 636-645; Gregory et al., 1993 Transplantation 1409-1418; Burke et al., 1999 J. Cardiovasc. Pharm 33: 829-835; Poon et al., 1996 J. Clin. Invest. 2277-2283; Jones et al., 2001, J. Immunol. Methods, 254: 85-98; Gildea et al., 2000 Biotechniques 29: 81-86).

III. MANUFACTURE

Within certain embodiments, the compound or composition may be applied on the patch by itself or in a carrier, which may be either polymeric, or non-polymeric. Representative examples of polymeric carriers include poly (ethylene-vinyl acetate), copolymers of lactic acid and glycolic acid, poly (caprolactone), poly (lactic

acid), copolymers of poly (lactic acid) and poly (caprolactone), gelatin, hyaluronic acid, collagen matrices, celluloses and albumen. Representative examples of other suitable carriers include, but are not limited to, ethanol; mixtures of ethanol and glycols (*e.g.*, ethylene glycol or propylene glycol); mixtures of ethanol and isopropyl myristate or ethanol, isopropyl myristate and water (*e.g.*, 55:5:40); mixtures of ethanol and eineol or D-limonene (with or without water); glycols (*e.g.*, ethylene glycol or propylene glycol) and mixtures of glycols such as propylene glycol and water, phosphatidyl glycerol, dioleoylphosphatidyl glycerol, Transcutol®, or terpinolene; mixtures of isopropyl myristate and 1-hexyl-2-pyrrolidone, N-dodecyl-2-piperidinone or 1-hexyl-2-pyrrolidone. Other representative examples of polymer formulations are described in U.S. Patent Nos. 5,716,981 and PCT patent application number PCT/CA00/01333, which are both incorporated by reference in their entirety.

Further examples of patents relating to polymers and their preparation include PCT Publication Nos. 98/12243, 98/19713, 98/41154, 99/07417, 00/33764, 00/21842, 00/09190, 00/09088, 00/09087, 2001/17575 and 2001/15526 (as well as their corresponding U.S. applications), and U.S. Patent Nos. 4,500,676, 4,582,865, 4,629,623, 4,636,524, 4,713,448, 4,795,741, 4,913,743, 5,069,899, 5,099,013, 5,128,326, 5,143,724, 5,153,174, 5,246,698, 5,266,563, 5,399,351, 5,525,348, 5,800,412, 5,837,226, 5,942,555, 5,997,517, 6,007,833, 6,071,447, 6,090,995, 6,106,473, 6,110,483, 6,121,027, 6,156,345, and 6,214,901, which, as noted above, are all incorporated by reference in their entirety.

Patches may be coated with compositions of the present invention in a variety of manners, including for example: (a) by directly affixing to the patch a formulation (*e.g.*, by either spraying the stent with a polymer/drug film, or by dipping the stent into a polymer/drug solution), (b) by coating the patch with a substance such as a hydrogel which will in turn absorb the composition, (c) by interweaving formulation-coated thread (or the polymer itself formed into a thread) into the patch structure, (d) by inserting the patch into a sleeve or mesh which is comprised of, or coated with, a formulation, or (e) constructing the patch itself with a composition.

Within preferred embodiments of the invention, the composition should firmly adhere to the patch during storage and at the time of implantation, and should not be dislodged from the patch when it is sutured to the blood vessel. The composition should also preferably not degrade during storage, prior to implantation, or when

warmed to body temperature after implantation inside the body. In addition, it should preferably coat the patch smoothly and evenly, with a uniform distribution of agents while not changing the patch shape. Within certain preferred embodiments of the invention, the formulation should be applied to only parts of the patch, leaving the rest of the patch uncoated, for example: (a) only the luminal side of the patch is coated, (b) only the edge of the patch is coated, (c) only one end of the patch is coated, (d) a stripe is left uncoated around the patch (e) part of the patch is coated with one agent and the rest of the patch is coated with another agent.

Within one preferred embodiments of the invention, the composition should provide a predictable, prolonged release of the factor into the surrounding tissue for 1 to 12 months after implantation. Within another embodiments of the invention, the composition should provide a predictable, slow release of the factor into the surrounding tissue for 1 to 10 years after implantation. Within another embodiments of the invention, the composition should provide a predictable, prolonged release of the factor into the surrounding tissue for 1 to 4 weeks after implantation. Within another embodiments of the invention, the composition should provide a predictable, fast release of the factor into the surrounding tissue for 1 to 7 days after implantation. Within another embodiments of the invention, the composition should provide a predictable, fast release of the factor into the surrounding tissue for 1 to 24 hours after implantation. Within another embodiments of the invention, the composition is not released into the surrounding tissue. Its presence on the patch forms a chemical barrier preventing cellular adhesion to the patch, cell migration onto the patch or cell proliferation on the patch. Within certain embodiments of the invention, compositions may be combined in order to achieve a desired effect (*e.g.*, several preparations may be combined in order to achieve both a quick and a slow or prolonged release of a given factor).

The compositions of the present invention may be formulated to contain more than one agent, to contain a variety of additional compounds, to have certain physical properties (*e.g.*, elasticity, a particular melting point, or a specified release rate).

In addition to the above properties, the composition should not cause significant turbulence in blood flow (not more than the patch itself would be expected to cause if it was uncoated).

The compositions and pharmaceutical compositions provided herein may be placed within containers, along with packaging material which provides instructions regarding the use of such materials. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients.

IV. APPLICATION

Primary closure and patch angioplasty are two techniques of arteriotomy closure used by surgeons after vascular procedures. In primary closure, the lips of the arterial wound are directly sutured to each other whereas an extra piece of material is sutured between the two lips during patch angioplasty. Patch angioplasty is preferred after procedures with a high rate of postoperative narrowing of the repaired vessel (endarterectomy of small carotid arteries or redo operations for example). The added piece of material maintains the original diameter of the blood vessel and induces favorable local hemodynamics that otherwise may lead to recurrent stenosis (Clagett et., 1986 J Vasc Surg. 3:10-23; Deriu et al., 1984 Stroke, 15: 972-979; Archie 2001 J Vasc Surg. 33: 495-503; Ouriel 1987 J Vasc Surg. 5:702-706; AbuRahma et al., 1998 J Vasc Surg 27: 222-234; Riles et al., 1990 Surgery 107: 10-12;).

Patch angioplasty is mainly performed in two vascular procedures at the present time, carotid endarterectomy and profundaplasty. However, vascular patches are also used in other vascular procedures, for example to repair iatrogenic or traumatic arterial injuries or to repair the arterial wall after resection of a saccular aneurysm. The present invention could be applied to any vascular patching procedure.

Patch angioplasty can be performed with autologous tissue (typically a segment of the patient's veins) or synthetic material (expanded polytetrafluoroethylene or Dacron). Vein patches have drawbacks such as aneurysmal degeneration and rupture (Archie et al., Surgery 1990, 107: 389-396). They require an additional incision to harvest the vein with associated morbidity. Vein harvest also increases operative time. The patient's veins may not be suitable for patching. Most importantly, the vein used for the patch will not be available for coronary artery bypass grafting should the patient require arterial reconstruction at a later time. For these reasons, the use of synthetic patches has become increasingly popular.

Patch angioplasty improves clinical outcome in many cases but it does not afford absolute protection against recurrent carotid stenosis (Awad et al., 1989 Stroke 20: 417-422; Eikelboom et al., 1988 J Vasc Surg 7: 240-247; AbuRahma et al., 1998 J Vasc Surg 27: 222-234; AbuRahma et al., 1998 J Vasc Surg 27: 222-234; Clagett et al., 1986 J Vasc Surg 3: 10-23). Synthetic patches implanted in the vasculature induce thrombogenic, inflammatory and hyperproliferative responses. Immediately after implantation, platelets bind to the luminal surface of the prosthesis, triggering the coagulation cascade and inducing thrombus formation. Thrombus may grow large enough to cause distal ischemia. Parts of the thrombus may also become dislodged and cause embolization of distal arterioles and capillaries. In the case of carotid artery patches, thrombus occlusion and embolization lead to stroke.

In the days following the procedure, inflammatory cells such as macrophages, lymphocytes and neutrophils adhere to the prosthetic lumen and also migrate into the peri-prosthetic space. These cells release cytokines that promote smooth muscle cell migration from the adjacent vessel on the luminal surface of the patch. The cells further proliferate on the patch and secrete extracellular matrix. Depending on the porosity of the patch material, cells may also migrate through the pores of the patch from the surrounding tissue into the lumen. In both cases, hyperplasia causes plaque formation on the luminal surface of the patch and the adjacent vessels within a few weeks. This reduces luminal area in the treated blood vessel, thus impeding blood flow to the distal tissue. The present invention involves coating synthetic patches with agents preventing inflammatory reaction, thrombus formation and intimal hyperplasia in order to inhibit restenosis of the treated vessel.

A. Carotid endarterectomy

A 10-cm long skin incision is made along the anterior border of the sternocleidomastoid muscle. After retraction of the muscle, the distal common carotid artery, the carotid bifurcation and the proximal segments of the internal and external carotid arteries are dissected. The three vessels are clamped. An arteriotomy is made in the common carotid artery extending antero-laterally through the plaque into the internal carotid artery beyond the distal extension of the plaque. The intimo-medial layer of the plaque is transected in the common carotid and the plaque is excised to the adventitia. A coated patch is trimmed and tapered to appropriate size (typically 7 cm

long with a 4 mm apex and a 7 mm bulb). The coated patch is placed along the edges of the arteriotomy to reconstruct the original shape of the vessel and to replace a significant portion of the endarterectomized wall of the artery. The coated patch is sutured to the edges of the arteriotomy with a continuous 7-0 polypropylene suture. Blood flow is restored by releasing all clamps and the skin wound is closed.

B. Profundaplasty

The common femoral artery and the profunda femoris artery (PFA) are isolated through a vertical groin incision. Once the branches distal to the end of the occlusive disease are controlled, the common femoral, superficial femoral and the PFA branches are clamped. An arteriotomy is performed, starting on the common femoral and extending down the PFA until the plaque ends. Endarterectomy of the involved common femoral and PFA is performed as needed. A coated patch is trimmed to size to achieve a smooth taper in the PFA to re-establish optimal flow characteristics in the repaired vessel. The coated patch is sutured to the edges of the arteriotomy with a continuous 7-0 polypropylene suture. Blood flow is restored by releasing all clamps and the skin wound is closed.

It should be obvious to one of skill in the art that the above-described compositions can be utilized to create variation in the Examples provided below, without deviating from the spirit and scope of the invention.

EXAMPLES

EXAMPLE 1

MANUFACTURE OF COATED PATCHES

A. Procedure for Sprayed Patches

The following describes a typical method using an oval 2 cm x 0.5 cm synthetic patch. For larger patches, larger volumes of polymer/drug solution are used.

Briefly, a sufficient quantity of polymer is weighed directly into a 20 mL glass scintillation vial, and sufficient DCM added in order to achieve a 2% w/v solution. The vial is then capped and mixed by hand in order to dissolve the polymer. The patch is then held in a vertical orientation with micro clamps connected to a holding apparatus 6 to 12 inches above the fume hood floor to enable horizontal spraying. Using an automatic pipette, a suitable volume (minimum 5ml) of the 2% polymer solution is transferred to a separate 20ml glass scintillation vial. An appropriate amount of paclitaxel is then added to the solution and dissolved by hand shaking.

To prepare for spraying, remove the cap of this vial and dip the barrel of a TLC atomizer into the polymer solution. Note that the reservoir of the atomizer need not be used in this procedure: the 20ml glass vial acts as a reservoir. Connect the nitrogen tank to the gas inlet of the atomizer. Gradually increase the pressure until atomization and spraying begins. Note the pressure and use this pressure throughout the procedure. To spray the patch use 5 second oscillating sprays with a 15 second dry time between sprays. After 5 sprays, rotate the patch 180° and spray the other side of the patch. During the dry time, finger crimp the gas line to avoid wastage of the spray. Spraying is continued until a suitable amount of polymer is deposited on the patch. The amount may be based on the specific patching application *in vivo*. To determine the amount, weigh the patch after spraying has been completed and the patch has dried. Subtract the original weight of the patch from the finished weight. This produces the amount of polymer (plus paclitaxel) applied to the patch. Store the coated patch in a sealed container.

B. Procedure for Dipped Patches

The following describes a typical method using a 2 cm x 0.5 cm oval synthetic patch. For larger patches, larger volumes of polymer/drug solution are used.

Weigh 2 g of polymer into a 20 mL glass scintillation vial and add 20 mL of DCM. Cap the vial and leave it for 2 hours to dissolve (hand shake the vial frequently to assist the dissolving process). Weigh a known amount of paclitaxel directly into an 8 mL glass vial and add 4 mL of the polymeric solution. Using a glass Pasteur pipette, dissolve paclitaxel by gently pumping the polymer solution. Once paclitaxel is dissolved, hold the glass vial in a near horizontal position (the sticky polymer solution will not flow out). Using tweezers, insert the patch into the vial all the way to the bottom. Allow the polymer solution to flow almost to the mouth of the vial by angling the mouth below horizontal and then restoring the vial to an angle slightly above the horizontal. Slowly remove the patch (approximately 30 seconds). Hold the patch in a vertical position to dry.

EXAMPLE 2

IN VITRO DRUG RELEASE RATE

Small pieces (0.5x0.5cm) of paclitaxel-coated patches (n=4) are placed in 14 mL glass tubes followed by 10 mL phosphate buffered saline (PBS, pH=7.4) containing 0.4 g/L albumin. The tubes are incubated at 37 °C with gentle rotational mixing at 8 rpm. At regular time intervals, 10 mL of supernatant are withdrawn for paclitaxel analysis and replaced with fresh PBS/albumin buffer. One mL of dichloromethane is added to the withdrawn supernatant and the tube is capped and shaken by hand for 1 minute to allow all the released paclitaxel to partition into the separate dichloromethane phase. The tubes are then centrifuged at 500xg for 1 minute, the 10 mL of top aqueous phase are withdrawn and discarded and the dichloromethane phase is evaporated under nitrogen at 50 °C for 20 minutes. One mL of a 60% acetonitrite in water (v/v) solution is added to each tube to solubilize the dried contents. These solutions are then analyzed for paclitaxel by HPLC using a Waters C18 Novapak column with a mobile phase composed of 58% acetonitrite / 5% methanol / 37% water at a flow rate of 1 mL / minute with detection at 232 nm. The HPLC method for quantitation of the released drug is chosen over other methods, such as radiolabelled assays, because the chromatographic method ensures that only paclitaxel molecules in

the intact (non-degraded) form are measured. A standard curve of paclitaxel dissolved in 60% acetonitrile: 40% water is obtained in the 0-50 μg/mL range and used to directly quantitate the amount of paclitaxel released.

EXAMPLE 3

IN VIVO PATCH EFFICACY

General anesthesia is induced into domestic swine. The neck region is shaved and the skin sterilized with cleansing solution. A vertical incision is made under sterile condition on one side of the neck and the common carotid artery is exposed. Two vascular clamps are placed on the artery to temporarily stop blood flow and an arteriotomy is performed between the clamps. The arteriotomy is closed with a synthetic patch. The animals are randomized into 4 groups of 5 pigs receiving a synthetic patch coated with (1) carrier polymer alone, (2) carrier polymer loaded with 1% paclitaxel, (3) carrier polymer loaded with 5% paclitaxel or (4) carrier polymer loaded with 10% paclitaxel. The clamps are released and the skin is closed.

The contralateral carotid artery is prepared in the same manner and a control uncoated patch is used to repair the arteriotomy. The animal is recovered.

The animals are sacrificed at 1 month and perfused with saline followed by 10% phosphate buffered formaldehyde for 30 minutes under 100mmHg pressure. The carotid arteries are removed and kept in the same fixative solution overnight. The specimens are then prepared for histology. Cross sections are cut and stained with H&E and Movat's stains. Histopathology of the tissue surrounding the patch is recorded. Morphometric analysis is performed to measure hyperplasia on the luminal surface of the patch and in adjacent vessels.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

I claim:

1. A surgical patch which releases an anti-inflammatory agent, an anti-platelet agent, an anticoagulant agent, a fibrinolytic agent, a cell-cycle inhibitor agent, and/or an anti-proliferative agent.

2. The surgical patch according to claim 1 wherein said patch is coated with one or more of said agents.

3. The surgical patch according to claim 1 wherein said agent further comprises a polymer.

4. The surgical patch according to claims 1, 2, 3, or 4 wherein said patch is a vascular patch.

5. The surgical patch according to claims 1, 2, 3, or 4 wherein said patch releases an anti-inflammatory agent.

6. The surgical patch according to claims 1, 2, 3, or 4 wherein said anti-inflammatory agent is aspirin, ibuprofen, or a glucocorticoid drug.

7. . The surgical patch according to claims 1, 2, 3, or 4 wherein said anti-coagulant agent is heparin or hirudin.

8. The surgical patch according to claims 1, 2, 3, or 4 wherein said fibrinolytic agent is tissue plasminogen activator, streptokinase, or, urokinase.

9. The surgical patch according to claims 1, 2, 3, or 4 wherein said cell cycle inhibitor is a taxane, a vinca alkaloid, a camptothecin, a podophyllotoxin, an anthracycline, a platinum compound, a nitrosourea, a nitroiidazole, a folic acid antagonist, a

cytidine analog, a pyrimidine analog, a purine analog, a nitrogen mustard., a hydroxyurea, a mytomycin, a benzamide, or a tetrazine.

10. The surgical patch according to claim 9 wherein said taxane is paclitaxel.

11. The surgical patch according to claim 9 wherein said vinca alkaloid is vinblastine or vincristine.

12. The surgical patch according to claim 9 wherein said podophyllotoxin is etoposide.

13. The surgical patch according to claim 9 wherein said anthracycline is doxorubicin or mitoxantrone.

14. The surgical patch according to claim 9 wherein said platinum compound is cisplatin or carboplatin.

15. The surgical patch according to claim 1 wherein said patch releases at least two or more of said agents.

16. The surgical patch according to claim 15 wherein said patch releases both an anti-inflammatory agent, and a cell-cycle inhibitor agent.

17. The surgical patch according to claim 1 wherein said patch is comprised of a synthetic material.

18. The surgical patch according to claim 1 wherein said patch is comprised of a biological tissue.

19. A method for closing an opening in a biological tissue, comprising applying a surgical patch according to any one of claims 1 to 18 to said opening.

20. The method according to claim 19 wherein said surgical patch is sutured in place.

21. The method according to claim 19 wherein said surgical patch is a vascular patch.

22. A method for making a drug-loaded surgical patch, comprising coating all or a portion of a surgical patch with an anti-inflammatory agent, an anti-platelet agent, an anticoagulant agent, a fibrinolytic agent, a cell-cycle inhibitor agent, and/or an anti-proliferative agent.

23. The method according to claim 22 wherein said patch is coated by dipping or spraying said agent on said patch.

24. The method according to claim 22 wherein said patch is coated with one or more of said agents.

25. The method according to claim 22 wherein said agent further comprises a polymer.

26. The method according to claim 22 wherein said patch is a vascular patch.

27. The method according to claims 22, 23, 24, or 25 wherein said patch releases an anti-inflammatory agent.

28. The method according to claims 22, 23, 24, or 25 wherein said anti-inflammatory agent is aspirin, ibuprofen, or a glucocorticoid drug.

29. . The method according to claims 22, 23, 24, or 25 wherein said anti-coagulant agent is heparin or hirudin.

30. The method according to claims 22, 23, 24, or 25 wherein said fibrinolytic agent is tissue plasminogen activator, streptokinase, or, urokinase.

31. The method according to claims 22, 23, 24, or 25 wherein said cell cycle inhibitor is a taxane, a vinca alkaloid, a camptothecin, a podophyllotoxin, an anthracycline, a platinum compound, a nitrosourea, a nitroiidazole, a folic acid antagonist, a cytidine analog, a pyrimidine analog, a purine analog, a nitrogen mustard., a hydroxyurea, a mytomycin, a benzamide, or a tetrazine.

32. The method according to claim 31 wherein said taxane is paclitaxel.

33. The method according to claim 31 wherein said vinca alkaloid is vinblastine or vincristine.

34. The method according to claim 31 wherein said podophyllotoxin is etoposide.

35. The method according to claim 31 wherein said anthracycline is doxorubicin or mitoxantrone.


36. The method according to claim 31 wherein said platinum compound is cisplatin or carboplatin.

37. The method according to claim 22 wherein said patch releases at least two or more of said agents.

38. The method according to claim 37 wherein said patch releases both an anti-inflammatory agent, and a cell-cycle inhibitor agent.

39. The method according to claim 22 wherein said patch is comprised of a synthetic material.

40. The method according to claim 22 wherein said patch is comprised of a biological tissue.



Title: CURVED SURGICAL PATCHES
Inventor(s): Pierre E. Signore Express Mail No. EV207783494US Docket No. 110129.426